Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10494785,t1/2alpha,Plasma half-life of thrombostatin had a t1/2alpha of 2.6 min and a t1/2beta of 24 min in rabbits.,Thrombostatin inhibits induced canine coronary thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494785/),min,2.6,4995,DB00945,Acetylsalicylic acid
,10494785,t1/2beta,Plasma half-life of thrombostatin had a t1/2alpha of 2.6 min and a t1/2beta of 24 min in rabbits.,Thrombostatin inhibits induced canine coronary thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494785/),min,24,4996,DB00945,Acetylsalicylic acid
,10494785,t1/2alpha,Ligating the renal arteries did not prolong clearance (t1/2alpha = 2.4 min; t1/2beta = 12 min).,Thrombostatin inhibits induced canine coronary thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494785/),min,2.4,4997,DB00945,Acetylsalicylic acid
,10494785,t1/2beta,Ligating the renal arteries did not prolong clearance (t1/2alpha = 2.4 min; t1/2beta = 12 min).,Thrombostatin inhibits induced canine coronary thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494785/),min,12,4998,DB00945,Acetylsalicylic acid
,23264940,flow rate,"The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),[ml] / [min],0.8,5160,DB00945,Acetylsalicylic acid
,23264940,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),min,3.0,5161,DB00945,Acetylsalicylic acid
,9044241,recovery,"The recovery of ASA, SA and SUA was between 90-105%.","A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044241/),%,90-105,5501,DB00945,Acetylsalicylic acid
,23081668,total run time,The total run time was 3.00 min; the developed method was validated in human plasma with a lower limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic acid.,Low dose aspirin estimation: an application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23081668/),min,3.00,5709,DB00945,Acetylsalicylic acid
,23081668,total run time,The total run time was 3.00 min; the developed method was validated in human plasma with a lower limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic acid.,Low dose aspirin estimation: an application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23081668/),ng,2.01,5710,DB00945,Acetylsalicylic acid
,1261159,T1/2,"Tolmetin, a nonsteroidal anti-inflammatory drug, is rapidly absorbed (10 to 20 min) and rapidly excreted (T1/2 congruent to 60 min) and shows a linear dose-plasma level response in the therapeutic dose range.",Absorption and excretion of tolemetin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261159/),min,60,6105,DB00945,Acetylsalicylic acid
,3705620,excretion,"The excretion of salicylic acid was found to be highly variable within the study panel (1.3-31% of dose in 12 h), and was related to both urine volume and pH.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,1.3-31,6997,DB00945,Acetylsalicylic acid
,3705620,excretion,"The excretion of the two salicyl glucuronides was highly variable, ranging from 0.8 to 42% of the dose.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,0.8 to 42,6998,DB00945,Acetylsalicylic acid
less,465097,concentration ratio,The concentration ratio was less than 1.3 at average salicylate concentrations above 20 mg/100 ml.,Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/465097/),,1.3,8210,DB00945,Acetylsalicylic acid
,23535530,half-life,"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily.",Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23535530/),h,12,8513,DB00945,Acetylsalicylic acid
,28526350,plasma half-life,"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),h,6.96,11725,DB00945,Acetylsalicylic acid
,28526350,plasma half-life,"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),h,7.01,11726,DB00945,Acetylsalicylic acid
,28526350,maximum plasma concentration (Cmax),"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),[μg] / [l],15.27,11727,DB00945,Acetylsalicylic acid
,28526350,maximum plasma concentration (Cmax),"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),[μg] / [l],23.01,11728,DB00945,Acetylsalicylic acid
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,91,11928,DB00945,Acetylsalicylic acid
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,99,11929,DB00945,Acetylsalicylic acid
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],616,11930,DB00945,Acetylsalicylic acid
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],1273,11931,DB00945,Acetylsalicylic acid
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],3882,11932,DB00945,Acetylsalicylic acid
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],8206,11933,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),min,25,12129,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),h,6,12130,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),min,35,12131,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),h,15,12132,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),h,3,12133,DB00945,Acetylsalicylic acid
,6113109,serum elimination half-lives (t1/2),"There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively.","Disposition of furobufen in mice, rats, dogs, and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113109/),h,20,12134,DB00945,Acetylsalicylic acid
,3708124,mean residence times,"Most of the formulations yield mean residence times for ASA of 0.3-1.0 h, which do not differ significantly (p greater than 0.05).",A pharmacokinetic approach to the establishment of biopharmaceutic characteristics of different acetylsalicylic acid formulations in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708124/),h,0.3-1.0,14709,DB00945,Acetylsalicylic acid
,3708124,apparent volume of distribution,"For most of the products the first-pass effect is about 40 per cent; the average values of the apparent volume of distribution and whole body clearance, corrected for the first-pass effect, are about 201 and 650 ml min-1, respectively.",A pharmacokinetic approach to the establishment of biopharmaceutic characteristics of different acetylsalicylic acid formulations in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708124/),[ml] / [min],201,14710,DB00945,Acetylsalicylic acid
,3708124,whole body clearance,"For most of the products the first-pass effect is about 40 per cent; the average values of the apparent volume of distribution and whole body clearance, corrected for the first-pass effect, are about 201 and 650 ml min-1, respectively.",A pharmacokinetic approach to the establishment of biopharmaceutic characteristics of different acetylsalicylic acid formulations in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708124/),[ml] / [min],650,14711,DB00945,Acetylsalicylic acid
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],407,17408,DB00945,Acetylsalicylic acid
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],294,17409,DB00945,Acetylsalicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],9.5,19458,DB00945,Acetylsalicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],13.2,19459,DB00945,Acetylsalicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],56.5,19460,DB00945,Acetylsalicylic acid
,10494706,Tmax (time to Cmax),"Mean Tmax (time to Cmax) for salicylic acid was 188 and 161 min in plasma and microdialysates, respectively.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),min,188,19461,DB00945,Acetylsalicylic acid
,10494706,Tmax (time to Cmax),"Mean Tmax (time to Cmax) for salicylic acid was 188 and 161 min in plasma and microdialysates, respectively.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),min,161,19462,DB00945,Acetylsalicylic acid
,10494706,dermis-to-plasma Cmax ratio,The dermis-to-plasma Cmax ratio was 0.16+/-0.04 (mean +/- SD) by microdialysis sampling and 0.25+/-0.09 by the suction blister fluid method.,Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),,0.16,19463,DB00945,Acetylsalicylic acid
,10494706,dermis-to-plasma Cmax ratio,The dermis-to-plasma Cmax ratio was 0.16+/-0.04 (mean +/- SD) by microdialysis sampling and 0.25+/-0.09 by the suction blister fluid method.,Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),,0.25,19464,DB00945,Acetylsalicylic acid
,1809699,relative bioavailability,"The results showed no difference between the area under concentration time curve (AUC0-infinity) ASA values of both formulations (p = 0.19), and buffered ASA relative bioavailability was 102.49% (= bioequivalence).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),%,102.49,20342,DB00945,Acetylsalicylic acid
,1809699,AUC0-30 min,A significant difference was found between the AUC0-30 min ASA values: 90.5 micrograms.,Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),μg,90.5,20343,DB00945,Acetylsalicylic acid
,1809699,time of maximum concentration,"The buffered ASA time of maximum concentration was shorter (28 +/- 8 min) than the plain one (38 +/- 19 min, p less than 0.05).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),min,28,20344,DB00945,Acetylsalicylic acid
,1809699,time of maximum concentration,"The buffered ASA time of maximum concentration was shorter (28 +/- 8 min) than the plain one (38 +/- 19 min, p less than 0.05).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),min,38,20345,DB00945,Acetylsalicylic acid
,2092574,T1/2ka,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,1.25,21536,DB00945,Acetylsalicylic acid
,2092574,T1/2ke,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,3.28,21537,DB00945,Acetylsalicylic acid
,2092574,ka,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),1/[h],0.5554,21538,DB00945,Acetylsalicylic acid
,2092574,ke,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),1/[h],0.2111,21539,DB00945,Acetylsalicylic acid
,2092574,Tmax,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,3.02,21540,DB00945,Acetylsalicylic acid
,2092574,Cmax,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),[μg] / [ml],331.46,21541,DB00945,Acetylsalicylic acid
,2092574,AUC,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),[μg] / [h·ml],2832.93,21542,DB00945,Acetylsalicylic acid
,2092574,total,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,10.9,21543,DB00945,Acetylsalicylic acid
,2092574,total,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,0.41,21544,DB00945,Acetylsalicylic acid
,2092574,excreted,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,10.9,21545,DB00945,Acetylsalicylic acid
,2092574,excreted,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,0.41,21546,DB00945,Acetylsalicylic acid
,6631686,half-life in blood,"The hydrolysis of aspirin in rat blood was 13 times faster than that in plasma, with an average half-life in blood of approximately 13 min.",Stability of aspirin in different media. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631686/),min,13,22030,DB00945,Acetylsalicylic acid
,10703994,limit of detection,The calibration graph was linear over the calibration range 0.2-12 microg ml(-1) plasma with a limit of detection of 0.1 microg ml(-1).,A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10703994/),[μg] / [ml],0.1,23623,DB00945,Acetylsalicylic acid
,21318583,inhibitory constant,"With an inhibitory constant of 0.08 nM for human FXa, apixaban has greater than 30,000-fold selectivity for FXa over other human coagulation proteases.","Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),nM,0.08,24193,DB00945,Acetylsalicylic acid
,21318583,association rate constant,It produces a rapid onset of inhibition of FXa with association rate constant of 20 μM⁻¹/s approximately and inhibits free as well as prothrombinase- and clot-bound FXa activity in vitro.,"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),[μM⁻¹] / [s],20,24194,DB00945,Acetylsalicylic acid
,3478694,partial pressure of oxygen at half-saturation,"Under physiological conditions, the partial pressure of oxygen at half-saturation of hemoglobin is increased to 29 mm Hg (1 mm Hg = 133.3 kPa), compared to 12 mm Hg for hemoglobin A, fully compensating for the absence of 2,3-bisphosphoglycerate outside of the erythrocyte.",HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478694/),hg·mm,29,29303,DB00945,Acetylsalicylic acid
,3478694,partial pressure of oxygen at half-saturation,"Under physiological conditions, the partial pressure of oxygen at half-saturation of hemoglobin is increased to 29 mm Hg (1 mm Hg = 133.3 kPa), compared to 12 mm Hg for hemoglobin A, fully compensating for the absence of 2,3-bisphosphoglycerate outside of the erythrocyte.",HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478694/),h·mm,12,29304,DB00945,Acetylsalicylic acid
,3478694,Hill coefficient,The Hill coefficient is 2.9.,HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478694/),,2.9,29305,DB00945,Acetylsalicylic acid
,3478694,half-life,"In the rat, the half-life of HbXL99 alpha in plasma, at a 15% volume exchange, is increased to 3.3 hr, compared to 90 min for hemoglobin A.",HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478694/),h,3.3,29306,DB00945,Acetylsalicylic acid
,3478694,half-life,"In the rat, the half-life of HbXL99 alpha in plasma, at a 15% volume exchange, is increased to 3.3 hr, compared to 90 min for hemoglobin A.",HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478694/),min,90,29307,DB00945,Acetylsalicylic acid
,8212113,plasma half-life,"The plasma half-life for alpha alpha Hb was 5 hours (administered dose, 2.4 g Hb/kg body weight).",Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212113/),h,5,29812,DB00945,Acetylsalicylic acid
,7309902,time to peak level,"Following a single dose, SSA was promptly absorbed (mean time to peak level 1.5 hour) and was eliminated from plasma with a mean half-life of 1.1 hour.","Absorption, biotransformation, and pharmacokinetics of salicylsalicylic acid in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309902/),h,1.5,30073,DB00945,Acetylsalicylic acid
,7309902,half-life,"Following a single dose, SSA was promptly absorbed (mean time to peak level 1.5 hour) and was eliminated from plasma with a mean half-life of 1.1 hour.","Absorption, biotransformation, and pharmacokinetics of salicylsalicylic acid in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309902/),h,1.1,30074,DB00945,Acetylsalicylic acid
,8656642,plasma clearance,TP-9201 had a plasma clearance of 9.9 +/- 2 ml/min/kg and a volume of distribution that was larger than plasma volume.,"Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),[ml] / [kg·min],9.9,31019,DB00945,Acetylsalicylic acid
,8656642,half life (t1/2),"After discontinuation of TP-9201, recovery of platelet aggregation had a half life (t1/2) of 2-3 h and was complete < or = 24 h.","Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656642/),h,2-3,31020,DB00945,Acetylsalicylic acid
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00945,Acetylsalicylic acid
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00945,Acetylsalicylic acid
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00945,Acetylsalicylic acid
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00945,Acetylsalicylic acid
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00945,Acetylsalicylic acid
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00945,Acetylsalicylic acid
,22057729,time to maximum plasma concentrations (T(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),min,17.5,32048,DB00945,Acetylsalicylic acid
,22057729,time to maximum plasma concentrations (T(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),min,45,32049,DB00945,Acetylsalicylic acid
,22057729,maximum plasma concentration (C(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),[μg] / [ml],13.8,32050,DB00945,Acetylsalicylic acid
,22057729,maximum plasma concentration (C(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),[μg] / [ml],4.4,32051,DB00945,Acetylsalicylic acid
,32268191,tmax,"We observed an earlier tmax (0.39 h vs. 2.00 h) and a higher Cmax (6.33 ± 2.37 μg/mL vs. 3.23 ± 1.28 μg/mL), whereas the AUC was only slightly different between both formulations.",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),h,0.39,32244,DB00945,Acetylsalicylic acid
,32268191,tmax,"We observed an earlier tmax (0.39 h vs. 2.00 h) and a higher Cmax (6.33 ± 2.37 μg/mL vs. 3.23 ± 1.28 μg/mL), whereas the AUC was only slightly different between both formulations.",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),h,2.00,32245,DB00945,Acetylsalicylic acid
,32268191,Cmax,"We observed an earlier tmax (0.39 h vs. 2.00 h) and a higher Cmax (6.33 ± 2.37 μg/mL vs. 3.23 ± 1.28 μg/mL), whereas the AUC was only slightly different between both formulations.",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),[μg] / [ml],6.33,32246,DB00945,Acetylsalicylic acid
,32268191,Cmax,"We observed an earlier tmax (0.39 h vs. 2.00 h) and a higher Cmax (6.33 ± 2.37 μg/mL vs. 3.23 ± 1.28 μg/mL), whereas the AUC was only slightly different between both formulations.",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),[μg] / [ml],3.23,32247,DB00945,Acetylsalicylic acid
,32268191,tmax,"The administration of the FDDT together with food had no marked effect on tmax (0.34 h vs. 0.39 h), but caused a decrease in Cmax compared to fasted intake (14.76 ± 4.81 μg/mL vs. 6.33 ± 2.37 μg/mL).",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),h,0.34,32248,DB00945,Acetylsalicylic acid
,32268191,tmax,"The administration of the FDDT together with food had no marked effect on tmax (0.34 h vs. 0.39 h), but caused a decrease in Cmax compared to fasted intake (14.76 ± 4.81 μg/mL vs. 6.33 ± 2.37 μg/mL).",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),h,0.39,32249,DB00945,Acetylsalicylic acid
,32268191,Cmax,"The administration of the FDDT together with food had no marked effect on tmax (0.34 h vs. 0.39 h), but caused a decrease in Cmax compared to fasted intake (14.76 ± 4.81 μg/mL vs. 6.33 ± 2.37 μg/mL).",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),[μg] / [ml],14.76,32250,DB00945,Acetylsalicylic acid
,32268191,Cmax,"The administration of the FDDT together with food had no marked effect on tmax (0.34 h vs. 0.39 h), but caused a decrease in Cmax compared to fasted intake (14.76 ± 4.81 μg/mL vs. 6.33 ± 2.37 μg/mL).",Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32268191/),[μg] / [ml],6.33,32251,DB00945,Acetylsalicylic acid
,25609600,flow rate,The system was operated at 25°C using a mobile phase consisting of acetonitrile and phosphate buffer (pH 3.0) in the gradient ratio at a flow rate of 1 mL min(-1) with ultraviolet detection monitored at 232 nm.,"Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609600/),[ml] / [min],1,32433,DB00945,Acetylsalicylic acid
,8980919,Cmax,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],10.04,33133,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],14.03,33134,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],86.51,33135,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.04,33136,DB00945,Acetylsalicylic acid
,8980919,t1/2,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.04,33137,DB00945,Acetylsalicylic acid
,8980919,t1/2,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.50,33138,DB00945,Acetylsalicylic acid
,8980919,tmax,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.50,33139,DB00945,Acetylsalicylic acid
,8980919,kel,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,0.633,33140,DB00945,Acetylsalicylic acid
,8980919,kel,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,0.463,33141,DB00945,Acetylsalicylic acid
,8980919,Cmax,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],43.84,33142,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],68.19,33143,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],171.59,33144,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [·h·ml],266.22,33145,DB00945,Acetylsalicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,7.37,33146,DB00945,Acetylsalicylic acid
,8980919,kel,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,7.37,33147,DB00945,Acetylsalicylic acid
,8980919,kel,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,19.30,33148,DB00945,Acetylsalicylic acid
,8980919,tmax,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,2.0,33149,DB00945,Acetylsalicylic acid
,8980919,tmax,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.0,33150,DB00945,Acetylsalicylic acid
,8980919,t1/2,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.25,33151,DB00945,Acetylsalicylic acid
,8980919,t1/2,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.184,33152,DB00945,Acetylsalicylic acid
,89124,plasma half-life,"A plasma half-life of approximately 45 hours is observed, permitting the use of single daily doses in therapy.",Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89124/),h,45,34564,DB00945,Acetylsalicylic acid
,25869458,kD,"The validated model was used to simulate bioequivalence trials at 3 dose schemes (100, 1000 and 3000 mg) and with 6 test formulations with decreasing in vivo dissolution rate constants versus the reference formulation (kD 8-0.25 h (-1)).",Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869458/),-1·h,8-0.25,36588,DB00945,Acetylsalicylic acid
,9635120,half life (t1/2),The half life (t1/2) for septic rats was 4.2 +/- 0.7 h and was significantly shorter than the t1/2 of non-septic rats (5.4 +/- 0.9 h).,Influence of sepsis on the plasma elimination pharmacokinetics of diaspirin crosslinked hemoglobin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9635120/),h,4.2,38050,DB00945,Acetylsalicylic acid
,9635120,t1/2,The half life (t1/2) for septic rats was 4.2 +/- 0.7 h and was significantly shorter than the t1/2 of non-septic rats (5.4 +/- 0.9 h).,Influence of sepsis on the plasma elimination pharmacokinetics of diaspirin crosslinked hemoglobin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9635120/),h,5.4,38051,DB00945,Acetylsalicylic acid
,12959298,release rate,The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h(-1).,Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959298/),[mg] / [h],10,39843,DB00945,Acetylsalicylic acid
,12959298,bioavailability,"The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90% relative to the solution, and drug release was not affected by co-administration of a standard breakfast.",Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959298/),%,90,39844,DB00945,Acetylsalicylic acid
,6873151,systemic availability,"The systemic availability of acetylsalicylic acid (ASA) after oral ingestion of 1 g in an effervescent formulation was 16.3 +/- 2.0% and 16.9 +/- 3.2% of the ingested dose in normal women and men, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),%,16.3,40819,DB00945,Acetylsalicylic acid
,6873151,systemic availability,"The systemic availability of acetylsalicylic acid (ASA) after oral ingestion of 1 g in an effervescent formulation was 16.3 +/- 2.0% and 16.9 +/- 3.2% of the ingested dose in normal women and men, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),%,16.9,40820,DB00945,Acetylsalicylic acid
,6873151,plasma half-life,"The average plasma half-life of ASA in each sex was also identical at 18.5 +/- 1.4 and 18.1 +/- 1.2 min, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),min,18.5,40821,DB00945,Acetylsalicylic acid
,6873151,plasma half-life,"The average plasma half-life of ASA in each sex was also identical at 18.5 +/- 1.4 and 18.1 +/- 1.2 min, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),min,18.1,40822,DB00945,Acetylsalicylic acid
,6873151,IC50,"The IC50 was 23.9 +/- 2.9 micrograms/ml in females and 22.5 +/- 2.7 micrograms/ml in males, which did not differ significantly.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],23.9,40823,DB00945,Acetylsalicylic acid
,6873151,IC50,"The IC50 was 23.9 +/- 2.9 micrograms/ml in females and 22.5 +/- 2.7 micrograms/ml in males, which did not differ significantly.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],22.5,40824,DB00945,Acetylsalicylic acid
,6873151,IC50,The inhibition by salicylic acid (SA) of the antiaggregatory effect of ASA was similar in both sexes with increases in IC50 to 33.5 +/- 5.1 micrograms/ml in females (p less than 0.02) and to 29.5 +/- 3.8 micrograms/ml in males (p less than 0.05).,Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],33.5,40825,DB00945,Acetylsalicylic acid
,6873151,IC50,The inhibition by salicylic acid (SA) of the antiaggregatory effect of ASA was similar in both sexes with increases in IC50 to 33.5 +/- 5.1 micrograms/ml in females (p less than 0.02) and to 29.5 +/- 3.8 micrograms/ml in males (p less than 0.05).,Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],29.5,40826,DB00945,Acetylsalicylic acid
,3735085,absolute bioavailability,"The estimated absolute bioavailability was 0.432 +/- 0.0213 and 0.527 +/- 0.0260 for enteric coated and plain aspirin, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),,0.432,45524,DB00945,Acetylsalicylic acid
,3735085,absolute bioavailability,"The estimated absolute bioavailability was 0.432 +/- 0.0213 and 0.527 +/- 0.0260 for enteric coated and plain aspirin, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),,0.527,45525,DB00945,Acetylsalicylic acid
,3735085,highest observed plasma concentration (Cmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),[μg] / [ml],10.9,45526,DB00945,Acetylsalicylic acid
,3735085,highest observed plasma concentration (Cmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),[μg] / [ml],13.6,45527,DB00945,Acetylsalicylic acid
,3735085,time to reach Cmax (tmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,26.6,45528,DB00945,Acetylsalicylic acid
,3735085,time to reach Cmax (tmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,31.0,45529,DB00945,Acetylsalicylic acid
,3735085,gastric emptying time,"The mean values for gastric emptying time, in vivo coating dissolution time, and in vivo disintegration/dissolution time of the tablet core for enteric coated aspirin are 48.7 +/- 7.23 min, 44.3 +/- 3.80 min, and 34.7 +/- 2.04 min, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,48.7,45530,DB00945,Acetylsalicylic acid
,3735085,disintegration/dissolution time,"The mean values for gastric emptying time, in vivo coating dissolution time, and in vivo disintegration/dissolution time of the tablet core for enteric coated aspirin are 48.7 +/- 7.23 min, 44.3 +/- 3.80 min, and 34.7 +/- 2.04 min, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,34.7,45531,DB00945,Acetylsalicylic acid
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.7,45863,DB00945,Acetylsalicylic acid
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.2,45864,DB00945,Acetylsalicylic acid
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],10.6,45865,DB00945,Acetylsalicylic acid
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],13.1,45866,DB00945,Acetylsalicylic acid
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],2.1,45867,DB00945,Acetylsalicylic acid
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],1.5,45868,DB00945,Acetylsalicylic acid
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,23.0,45869,DB00945,Acetylsalicylic acid
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,21.9,45870,DB00945,Acetylsalicylic acid
,2203580,terminal phase half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h).",Clinical pharmacokinetics of ketoprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203580/),h,1 to 3,46734,DB00945,Acetylsalicylic acid
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,137,47440,DB00945,Acetylsalicylic acid
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,65,47441,DB00945,Acetylsalicylic acid
,1501071,bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,100,47766,DB00945,Acetylsalicylic acid
,1501071,oral bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,58.8,47767,DB00945,Acetylsalicylic acid
,9653928,limit of detection,The limit of detection was determined as 546 amol of ASA at a signal-to-noise ratio of 10:1.,Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin and guaimesal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653928/),amol,546,51784,DB00945,Acetylsalicylic acid
,9653928,signal-to-noise ratio,The limit of detection was determined as 546 amol of ASA at a signal-to-noise ratio of 10:1.,Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin and guaimesal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653928/),,10:1,51785,DB00945,Acetylsalicylic acid
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],9.76,54725,DB00945,Acetylsalicylic acid
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],24.19,54726,DB00945,Acetylsalicylic acid
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],36.59,54727,DB00945,Acetylsalicylic acid
,1773551,time to achieve maximum aspirin concentrations,"There were no significant differences (p greater than 0.05) in the mean time to achieve maximum aspirin concentrations between 'Cardiprin' 100 (0.48 h) and 'Platelin' (0.35 h), but this was significantly prolonged (p less than 0.001) for 'Astrix' 100 (3.73 h) and even more prolonged for 'Cartia' (6.84 h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),h,0.48,54804,DB00945,Acetylsalicylic acid
,1773551,time to achieve maximum aspirin concentrations,"There were no significant differences (p greater than 0.05) in the mean time to achieve maximum aspirin concentrations between 'Cardiprin' 100 (0.48 h) and 'Platelin' (0.35 h), but this was significantly prolonged (p less than 0.001) for 'Astrix' 100 (3.73 h) and even more prolonged for 'Cartia' (6.84 h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),h,0.35,54805,DB00945,Acetylsalicylic acid
,1773551,time to achieve maximum aspirin concentrations,"There were no significant differences (p greater than 0.05) in the mean time to achieve maximum aspirin concentrations between 'Cardiprin' 100 (0.48 h) and 'Platelin' (0.35 h), but this was significantly prolonged (p less than 0.001) for 'Astrix' 100 (3.73 h) and even more prolonged for 'Cartia' (6.84 h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),h,3.73,54806,DB00945,Acetylsalicylic acid
,1773551,time to achieve maximum aspirin concentrations,"There were no significant differences (p greater than 0.05) in the mean time to achieve maximum aspirin concentrations between 'Cardiprin' 100 (0.48 h) and 'Platelin' (0.35 h), but this was significantly prolonged (p less than 0.001) for 'Astrix' 100 (3.73 h) and even more prolonged for 'Cartia' (6.84 h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),h,6.84,54807,DB00945,Acetylsalicylic acid
,1773551,areas under the plasma concentration-time curves,"Similar between-formulation differences were seen in the areas under the plasma concentration-time curves, for which the rank order was 'Cardiprin' 100 (1.60 mg/L.h) = 'Platelin' (1.54 mg/L.h) greater than 'Astrix' 100 (0.73 mg/L.h) greater than 'Cartia' (0.56 mg/L.h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),[mg] / [h·l],1.60,54808,DB00945,Acetylsalicylic acid
,1773551,areas under the plasma concentration-time curves,"Similar between-formulation differences were seen in the areas under the plasma concentration-time curves, for which the rank order was 'Cardiprin' 100 (1.60 mg/L.h) = 'Platelin' (1.54 mg/L.h) greater than 'Astrix' 100 (0.73 mg/L.h) greater than 'Cartia' (0.56 mg/L.h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),[mg] / [h·l],1.54,54809,DB00945,Acetylsalicylic acid
,1773551,areas under the plasma concentration-time curves,"Similar between-formulation differences were seen in the areas under the plasma concentration-time curves, for which the rank order was 'Cardiprin' 100 (1.60 mg/L.h) = 'Platelin' (1.54 mg/L.h) greater than 'Astrix' 100 (0.73 mg/L.h) greater than 'Cartia' (0.56 mg/L.h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),[mg] / [h·l],0.73,54810,DB00945,Acetylsalicylic acid
,1773551,areas under the plasma concentration-time curves,"Similar between-formulation differences were seen in the areas under the plasma concentration-time curves, for which the rank order was 'Cardiprin' 100 (1.60 mg/L.h) = 'Platelin' (1.54 mg/L.h) greater than 'Astrix' 100 (0.73 mg/L.h) greater than 'Cartia' (0.56 mg/L.h).",Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773551/),[mg] / [h·l],0.56,54811,DB00945,Acetylsalicylic acid
,29124988,volume of distribution,"Butalbital is a small molecule (approximately 220 Da), with 26% protein binding, a 0.8 L/kg volume of distribution, and is eliminated nearly 80% unchanged in the urine.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[l] / [kg],0.8,56164,DB00945,Acetylsalicylic acid
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mg] / [dl],46.4,56165,DB00945,Acetylsalicylic acid
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mM] / [l],3.4,56166,DB00945,Acetylsalicylic acid
,29124988,total body elimination,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),%,60,56167,DB00945,Acetylsalicylic acid
,29124988,clearance,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[ml] / [min],233-300,56168,DB00945,Acetylsalicylic acid
,11878089,Peak serum ASA concentrations (Cmax),Peak serum ASA concentrations (Cmax) were 6.8 mg/l for oral Lys-ASA and 2.7 mg/l for ASA per os.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],6.8,59082,DB00945,Acetylsalicylic acid
,11878089,Peak serum ASA concentrations (Cmax),Peak serum ASA concentrations (Cmax) were 6.8 mg/l for oral Lys-ASA and 2.7 mg/l for ASA per os.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],2.7,59083,DB00945,Acetylsalicylic acid
,11878089,tmax,The corresponding tmax-values were 14.2 and 38.0 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,14.2,59084,DB00945,Acetylsalicylic acid
,11878089,tmax,The corresponding tmax-values were 14.2 and 38.0 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,38.0,59085,DB00945,Acetylsalicylic acid
,11878089,Absolute bioavailabilities,"Absolute bioavailabilities for 500 mg doses were 75.4 and 63.4 pour cent, respectively.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),cent·pour,75.4,59086,DB00945,Acetylsalicylic acid
,11878089,Absolute bioavailabilities,"Absolute bioavailabilities for 500 mg doses were 75.4 and 63.4 pour cent, respectively.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),cent·pour,63.4,59087,DB00945,Acetylsalicylic acid
,11878089,Cmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],2.7,59088,DB00945,Acetylsalicylic acid
,11878089,Cmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],15.9,59089,DB00945,Acetylsalicylic acid
,11878089,tmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,14.2,59090,DB00945,Acetylsalicylic acid
,11878089,half-life,The shortest half-life was found after i.v. injection with 7.5 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,7.5,59091,DB00945,Acetylsalicylic acid
,15684280,terminal half-life,"The median terminal half-life was 72.2 (25th, 75th: 28.4, 72.5) h.",Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684280/),h,72.2,59982,DB00945,Acetylsalicylic acid
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"13,083",65198,DB00945,Acetylsalicylic acid
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"7,255",65199,DB00945,Acetylsalicylic acid
,3944270,fractional elimination,"The fractional elimination of 2,3-dinor-TxB2 was independent of the rate of TxB2 infusion and averaged 5.3 +/- 0.8%.",Estimated rate of thromboxane secretion into the circulation of normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944270/),%,5.3,65842,DB00945,Acetylsalicylic acid
,3944270,rate of entry,"Interpolation of metabolite values obtained in aspirin-free periods onto the linear relationship between the quantities of infused TxB2 and the amount of metabolite excreted in excess of control values (y = 0.0066x, r = 0.975, P less than 0.001) permitted calculation of the mean rate of entry of endogenous TxB2 into the circulation as 0.11 ng/kg X min.",Estimated rate of thromboxane secretion into the circulation of normal humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944270/),[ng] / [kg·min],0.11,65843,DB00945,Acetylsalicylic acid
,3944270,apparent half-life,The rate of disappearance of immunoreactive TxB2 from the circulation was monoexponential over the first 10 min with an apparent half-life of 7 min.,Estimated rate of thromboxane secretion into the circulation of normal humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944270/),min,7,65844,DB00945,Acetylsalicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,16.9,67383,DB00945,Acetylsalicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,8.6,67384,DB00945,Acetylsalicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,2.6,67385,DB00945,Acetylsalicylic acid
,7180498,peak concentration,All subjects had clearly measureable amounts of ASA in plasma after oral intake of a sustained release preparation with an average peak concentration of 15 mumol/l.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],15,67386,DB00945,Acetylsalicylic acid
,7180498,Peak concentration,"Peak concentration after an effervescent and plain formulation was on the average 80 and 40 mumol/l, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],80,67387,DB00945,Acetylsalicylic acid
,7180498,Peak concentration,"Peak concentration after an effervescent and plain formulation was on the average 80 and 40 mumol/l, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],40,67388,DB00945,Acetylsalicylic acid
,7180498,Half-life,Half-life of ASA in plasma was 18.1 +/- 1.2 min.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),min,18.1,67389,DB00945,Acetylsalicylic acid
,7180498,plasma half-life,Average plasma half-life of salicylic acid (SA) was similar after the three different administration forms with values between 3.0 and 3.7 hrs.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),h,3,67390,DB00945,Acetylsalicylic acid
,29403744,flow rate,"The reconstituted samples were chromatographed on a Zorbax SB-C18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),[ml] / [min],0.8,67953,DB00945,Acetylsalicylic acid
,29403744,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),min,2.0,67954,DB00945,Acetylsalicylic acid
,428733,elimination half-time,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),h,3.71,68406,DB00945,Acetylsalicylic acid
,428733,elimination half-time,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),h,2.38,68407,DB00945,Acetylsalicylic acid
,428733,volume of distribution,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),l,5.51,68408,DB00945,Acetylsalicylic acid
,428733,volume of distribution,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),l,3.83,68409,DB00945,Acetylsalicylic acid
greater,1874875,total urinary recovery,The total urinary recovery of salicylic acid after a single 1.2-g dose of soluble aspirin was greater than 90%.,Novel direct high-performance liquid chromatographic method for determination of salicylate glucuronide conjugates in human urine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874875/),%,90,70883,DB00945,Acetylsalicylic acid
,7752308,volume of distribution at steady-state Vd(ss),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [kg],0.2,72297,DB00945,Acetylsalicylic acid
,7752308,volume of distribution by the area method Vd(area),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [kg],0.38,72298,DB00945,Acetylsalicylic acid
,7752308,mean residence time (MRT),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),h,6.5,72299,DB00945,Acetylsalicylic acid
,7752308,mean residence time in peripheral tissues (MRTp),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),h,2.6,72300,DB00945,Acetylsalicylic acid
,7752308,total body clearance (Cl),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [h·kg],0.032,72301,DB00945,Acetylsalicylic acid
,7752308,elimination rate constant (beta),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),1/[h],0.097,72302,DB00945,Acetylsalicylic acid
,8968267,half-life,The half-life of diaspirin cross-linked hemoglobin solution was 2.5 hrs for the 25- and 50-mg/kg doses and 3.3 hrs for the 100-mg/kg dose.,Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968267/),h,2.5,72738,DB00945,Acetylsalicylic acid
,8968267,half-life,The half-life of diaspirin cross-linked hemoglobin solution was 2.5 hrs for the 25- and 50-mg/kg doses and 3.3 hrs for the 100-mg/kg dose.,Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968267/),h,3.3,72739,DB00945,Acetylsalicylic acid
,6930483,plasma elimination half-life,"The plasma elimination half-life of the drug, when in solid dosage form, was found to be in the range of 19-26 h, justifying once-a-day dosage.",Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6930483/),h,19-26,73111,DB00945,Acetylsalicylic acid
,18478192,maximum plasma concentration,The maximum plasma concentration of CAS was found to be 0.38 mg L(-1) with t (max) of 0.72 h.,Pharmacokinetic study of copper (II) acetylsalicylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[mg] / [l],0.38,73481,DB00945,Acetylsalicylic acid
,18478192,t (max),The maximum plasma concentration of CAS was found to be 0.38 mg L(-1) with t (max) of 0.72 h.,Pharmacokinetic study of copper (II) acetylsalicylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),h,0.72,73482,DB00945,Acetylsalicylic acid
,18478192,plasma half-life,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),h,8.67,73483,DB00945,Acetylsalicylic acid
,18478192,clearance,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[l] / [h],66.30,73484,DB00945,Acetylsalicylic acid
,18478192,volume of distribution,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[l] / [kg],829,73485,DB00945,Acetylsalicylic acid
,12870876,Relative bioavailability,Relative bioavailability for the low-dose treatment was 0.5 compared to oil of wintergreen.,Plasma salicylate from methyl salicylate cream compared to oil of wintergreen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12870876/),,0.5,74418,DB00945,Acetylsalicylic acid
,26168972,limit of detection (LOD),The limit of detection (LOD) was 8 mg/L and the lower limit of quantification (LLOQ) was 10 mg/L.,Personalized monitoring of therapeutic salicylic acid in dried blood spots using a three-layer setup and desorption electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26168972/),[mg] / [l],8,74798,DB00945,Acetylsalicylic acid
,26168972,Recovery rates,Recovery rates in method verification by LC-MS/MS were 97 to 101% for blinded samples.,Personalized monitoring of therapeutic salicylic acid in dried blood spots using a three-layer setup and desorption electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26168972/),%,97 to 101,74799,DB00945,Acetylsalicylic acid
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB00945,Acetylsalicylic acid
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB00945,Acetylsalicylic acid
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB00945,Acetylsalicylic acid
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB00945,Acetylsalicylic acid
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB00945,Acetylsalicylic acid
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB00945,Acetylsalicylic acid
,7061727,maximal plasma salicylate concentration (Cpmax),Both AC (44.16 +/- 16.85 microgram/ml) and AC + SS (58.61 +/- 10.63 microgram/ml) decreased (P less than 0.001) the maximal plasma salicylate concentration (Cpmax) compared to control (86.61 +/- 12.69 microgram/ml).,Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),[μg] / [ml],86.61,75596,DB00945,Acetylsalicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,57.88,75597,DB00945,Acetylsalicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,61.00,75598,DB00945,Acetylsalicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,93.73,75599,DB00945,Acetylsalicylic acid
,19444799,flow rate,"The mobile phase consisting of a mixture of water phase (containing 10 mmol L(-1) 18-crown-6 ether, 5 mmol L(-1) octylamine and 5 mmol L(-1) sodium dihydrogen phosphate, pH adjusted to 6.0 with phosphoric acid) and acetonitrile in the ratio 70:30 (v/v) was delivered isocraticly at a flow rate of 1.0 mL min(-1).",Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19444799/),[ml] / [min],1.0,75704,DB00945,Acetylsalicylic acid
,3395669,Steady-state SA concentrations,Steady-state SA concentrations fell 23 per cent during the 4-week study period (mean +/- SD: 239 +/- 35 to 183 +/- 23 micrograms ml-1; p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[μg] / [ml],239,76907,DB00945,Acetylsalicylic acid
,3395669,Steady-state SA concentrations,Steady-state SA concentrations fell 23 per cent during the 4-week study period (mean +/- SD: 239 +/- 35 to 183 +/- 23 micrograms ml-1; p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[μg] / [ml],183,76908,DB00945,Acetylsalicylic acid
,3395669,Vmax SU,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.93,76909,DB00945,Acetylsalicylic acid
,3395669,Vmax SU,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],1.68,76910,DB00945,Acetylsalicylic acid
,3395669,Vmax SPG,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.09,76911,DB00945,Acetylsalicylic acid
,3395669,Vmax SPG,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.19,76912,DB00945,Acetylsalicylic acid
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,82.7,77492,DB00945,Acetylsalicylic acid
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,98.5,77493,DB00945,Acetylsalicylic acid
,22489610,time to maximum concentration,"Ticagrelor is rapidly absorbed, with a median time to maximum concentration of 1.3-2.0 hours.","Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22489610/),h,1.3-2.0,79556,DB00945,Acetylsalicylic acid
,1127135,half-life,"The mean half-life of the drug in man is 13 hours, close to ideal for twice-daily administration.",Naproxen metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127135/),h,13,80169,DB00945,Acetylsalicylic acid
,12959636,area under the concentration-time curve (AUC24),"For aspirin 80 mg/day, 24-hour area under the concentration-time curve (AUC24) was similar on days 1 and 7 (569 +/- 339 vs 605 +/- 377 microg.",Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959636/),μg,569,80752,DB00945,Acetylsalicylic acid
,12959636,area under the concentration-time curve (AUC24),"For aspirin 80 mg/day, 24-hour area under the concentration-time curve (AUC24) was similar on days 1 and 7 (569 +/- 339 vs 605 +/- 377 microg.",Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959636/),μg,605,80753,DB00945,Acetylsalicylic acid
,2072775,time elapsed to achieve maximum plasma concentrations in,"The time elapsed to achieve maximum plasma concentrations in the systemic circulation was 1 to 4 hours, as compared with 0.25 to 1.5 hours with other conventional preparations of ASA.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),h,1 to 4,81368,DB00945,Acetylsalicylic acid
,2072775,time elapsed to achieve maximum plasma concentrations in,"The time elapsed to achieve maximum plasma concentrations in the systemic circulation was 1 to 4 hours, as compared with 0.25 to 1.5 hours with other conventional preparations of ASA.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),h,0.25 to 1.5,81369,DB00945,Acetylsalicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],1.2,81370,DB00945,Acetylsalicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],4.8,81371,DB00945,Acetylsalicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],12,81372,DB00945,Acetylsalicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],14,81373,DB00945,Acetylsalicylic acid
,902456,peak plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],194 to 340,84173,DB00945,Acetylsalicylic acid
,902456,peak codeine plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],102 to 140,84174,DB00945,Acetylsalicylic acid
,902456,plasma t1/2,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),h,3.32,84175,DB00945,Acetylsalicylic acid
,902456,volume of distribution,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[l] / [kg],5.1,84176,DB00945,Acetylsalicylic acid
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,42,84177,DB00945,Acetylsalicylic acid
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,53,84178,DB00945,Acetylsalicylic acid
,17694544,maximum SA concentration (Cmax),The mean (SD) maximum SA concentration (Cmax) was 0.81 (0.32) microg/mL and 56.4 (14.2) microg/mL.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),[μg] / [ml],0.81,84221,DB00945,Acetylsalicylic acid
,17694544,maximum SA concentration (Cmax),The mean (SD) maximum SA concentration (Cmax) was 0.81 (0.32) microg/mL and 56.4 (14.2) microg/mL.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),[μg] / [ml],56.4,84222,DB00945,Acetylsalicylic acid
,17694544,safety margin ratio,The AUC-based safety margin ratio was 50:1.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),,50,84223,DB00945,Acetylsalicylic acid
,17694544,Cmax,Plasma SA Cmax values were achieved from 1.4 to 3.5 h after topical application and from 0.5 to 1.5 h after oral aspirin.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),h,1.4 to 3.5,84224,DB00945,Acetylsalicylic acid
,17694544,Cmax,Plasma SA Cmax values were achieved from 1.4 to 3.5 h after topical application and from 0.5 to 1.5 h after oral aspirin.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),h,0.5 to 1.5,84225,DB00945,Acetylsalicylic acid
,8750369,Peak plasma ASA levels,Peak plasma ASA levels of 1 microgram/mL were achieved within 30 minutes.,Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),[μg] / [ml],1,84915,DB00945,Acetylsalicylic acid
,8750369,Peak plasma SA levels,Peak plasma SA levels of approximately 4 micrograms/mL were attained in 1 hour.,Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),[μg] / [ml],4,84916,DB00945,Acetylsalicylic acid
,8750369,terminal half-lives (t1/2),"The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 hours, respectively.",Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),h,0.4,84917,DB00945,Acetylsalicylic acid
,8750369,terminal half-lives (t1/2),"The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 hours, respectively.",Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),h,2.1,84918,DB00945,Acetylsalicylic acid
,3680588,peak concentration,"The mean peak concentration of aspirin was 6.5 micrograms/mL in plasma (range, 4.9-8.9 micrograms/mL), reached in 26 minutes (range, 13-33 minutes).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],6.5,85256,DB00945,Acetylsalicylic acid
,3680588,half-life,The half-life of aspirin was 31 minutes.,Disposition of aspirin and its metabolites in the semen of man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),min,31,85257,DB00945,Acetylsalicylic acid
,3680588,peak concentration,"The mean peak concentration of salicylate in plasma was 49 micrograms/mL (range, 42-62 micrograms/mL), reached in 2.5 hours (range, 2.0-2.8 hours).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],49,85258,DB00945,Acetylsalicylic acid
,3680588,concentration ratio,Salicylate distributed rapidly into semen and maintained a concentration ratio (semen/plasma) of 0.15.,Disposition of aspirin and its metabolites in the semen of man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),,0.15,85259,DB00945,Acetylsalicylic acid
,428423,half-life,"The half-life of TXA2 in blood was 30-47 sec, a similar value to that found in aqueous solutions at 37 degrees C. PGH2 was also converted in blood to other product(s) which contracted RSS and RC, relaxed RbCA and RbMA but had little effect on RbA.",Biotransformation and cardiovascular effects of arachidonic acid in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428423/),s,30-47,85811,DB00945,Acetylsalicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,6.08,86751,DB00945,Acetylsalicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,3.32,86752,DB00945,Acetylsalicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,6.95,86753,DB00945,Acetylsalicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,4.55,86754,DB00945,Acetylsalicylic acid
,23906222,maximal plasma concentration of SA (C max),"The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96.93 ± 8.06 and 91.76 ± 9.64 µg/ml, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],96.93,86755,DB00945,Acetylsalicylic acid
,23906222,maximal plasma concentration of SA (C max),"The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96.93 ± 8.06 and 91.76 ± 9.64 µg/ml, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],91.76,86756,DB00945,Acetylsalicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.24,86757,DB00945,Acetylsalicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.24,86758,DB00945,Acetylsalicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.78,86759,DB00945,Acetylsalicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.59,86760,DB00945,Acetylsalicylic acid
,23906222,bioavailability,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],6.9,86761,DB00945,Acetylsalicylic acid
,23906222,C max,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],6.9,86762,DB00945,Acetylsalicylic acid
,23906222,C max,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],8.6,86763,DB00945,Acetylsalicylic acid
,28302764,half maximal inhibitory concentration,The half maximal inhibitory concentration of 18F-GP1 to GPIIb/IIIa was 20 nM.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),nM,20,87536,DB00945,Acetylsalicylic acid
,28302764,clot-to-blood ratio,18F-GP1 bound to thrombi with a mean clot-to-blood ratio of 95.,"18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302764/),,95,87537,DB00945,Acetylsalicylic acid
,7514021,total body clearance,"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg·min],37.9,87913,DB00945,Acetylsalicylic acid
,7514021,total body clearance,"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg·min],38.5,87914,DB00945,Acetylsalicylic acid
,7514021,volume of distribution (Vd),"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg],385.5,87915,DB00945,Acetylsalicylic acid
,7514021,volume of distribution (Vd),"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg],397.1.1,87916,DB00945,Acetylsalicylic acid
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00945,Acetylsalicylic acid
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00945,Acetylsalicylic acid
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00945,Acetylsalicylic acid
,28103874,maximum concentrations,"In the 25 mg/kg group, maximum concentrations were detected after 2 h (urine, 2785 μg/mL) and 1.5 h (plasma, 23 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],2785,90639,DB00945,Acetylsalicylic acid
,28103874,maximum concentrations,"In the 25 mg/kg group, maximum concentrations were detected after 2 h (urine, 2785 μg/mL) and 1.5 h (plasma, 23 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],23,90640,DB00945,Acetylsalicylic acid
,28103874,maximum concentrations,"In the 50 mg/kg group, maximum concentrations were observed after 5 h (urine, 3915 μg/mL) and 1.5 h (plasma, 45 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],3915,90641,DB00945,Acetylsalicylic acid
,28103874,maximum concentrations,"In the 50 mg/kg group, maximum concentrations were observed after 5 h (urine, 3915 μg/mL) and 1.5 h (plasma, 45 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],45,90642,DB00945,Acetylsalicylic acid
,28103874,plasma half-life,The plasma half-life calculated for SA varied between 5.0 and 5.7 h.,Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),h,5.0 and 5.7,90643,DB00945,Acetylsalicylic acid
,28103874,IC50,"For ASA, IC50 were 0.50 μg/mL (COX-1) and 5.14 μg/mL (COX-2).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],0.50,90644,DB00945,Acetylsalicylic acid
,28103874,IC50,"For ASA, IC50 were 0.50 μg/mL (COX-1) and 5.14 μg/mL (COX-2).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],5.14,90645,DB00945,Acetylsalicylic acid
,1379152,half-life,It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours).,"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379152/),h,2,90807,DB00945,Acetylsalicylic acid
above,2609979,Recoveries,Recoveries of salicylic acid were found to be above 98.4% and the method was linear from 8-160 micrograms with a correlation coefficient of 0.9999.,[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),%,98.4,91918,DB00945,Acetylsalicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,2.3374,91919,DB00945,Acetylsalicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,0.9846,91920,DB00945,Acetylsalicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91921,DB00945,Acetylsalicylic acid
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],361.63,91922,DB00945,Acetylsalicylic acid
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91923,DB00945,Acetylsalicylic acid
,25402445,Tmax,Acetylsalicylic acid was rapidly absorbed with a mean Tmax of 27 ± 8 min.,Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),min,27,92499,DB00945,Acetylsalicylic acid
,25402445,Tmax,Tmax of salicylic acid was 69 ± 21 min.,Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),min,69,92500,DB00945,Acetylsalicylic acid
,25402445,Cmax,"Mean Cmax was 1·8 ± 0·6 mg/L and 7·6 ± 1·4 for acetylsalicylic acid and salicylic acid, respectively.",Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),[mg] / [l],1·8,92501,DB00945,Acetylsalicylic acid
,25402445,Cmax,"Mean Cmax was 1·8 ± 0·6 mg/L and 7·6 ± 1·4 for acetylsalicylic acid and salicylic acid, respectively.",Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),,7·6,92502,DB00945,Acetylsalicylic acid
,26369775,plasma protein binding,The plasma protein binding of vonoprazan is 80% in healthy subjects.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,80,92503,DB00945,Acetylsalicylic acid
,26369775,apparent volume of distribution,It distributes extensively into tissues with a mean apparent volume of distribution of 1050 L.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),l,1050,92504,DB00945,Acetylsalicylic acid
,26369775,pKa,"Being a base with pKa of 9.6 and with acid-resistant properties, vonoprazan is highly concentrated in the acidic canaliculi of the gastric parietal cells and elicited an acid suppression effect for longer than 24 h after the administration of 20 mg.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),,9.6,92505,DB00945,Acetylsalicylic acid
,26369775,apparent terminal half-life,The mean apparent terminal half-life of the drug is approximately 7.7 h in healthy adults.,"The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),h,7.7,92506,DB00945,Acetylsalicylic acid
,26369775,pH >4 holding time ratios,"During repeated dosing of 20 mg once daily, the 24-h intragastric pH >4 holding time ratios were 63 and 83 % on days 1 and 7, respectively.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,63,92507,DB00945,Acetylsalicylic acid
,26369775,pH >4 holding time ratios,"During repeated dosing of 20 mg once daily, the 24-h intragastric pH >4 holding time ratios were 63 and 83 % on days 1 and 7, respectively.","The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26369775/),%,83,92508,DB00945,Acetylsalicylic acid
,11642382,maximum blood plasma levels,The maximum blood plasma levels were 5.2 microg/mL.,Slow release of acetylsalicylic acid by intravitreal silicone oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642382/),[μg] / [ml],5.2,92547,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,6,92633,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,54,92634,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,65.2,92635,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,65.2,92636,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,31.0,92637,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,1432.6,92638,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,356.8,92639,DB00945,Acetylsalicylic acid
,8484010,plasma concentrations,"When 10 micrograms/kg of TxB2 was intravenously administered to dogs in which endogenous production of prostanoids was blocked by aspirin, the plasma concentrations of 11-dehydro TxB2 before and 2, 5, 15, 60 min after TxB2 administration were 6.2 +/- 1.4, 54.2 +/- 5.0, 65.2 +/- 14.3, 65.2 +/- 16.4 and 31.0 +/- 7.5 pg/ml, while the corresponding TxB2 levels were 20.1 +/- 3.1, 3143.3 +/- 379.5, 1432.6 +/- 120.5, 356.8 +/- 38.9, and 128.9 +/- 13.6 pg/ml, respectively.",11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8484010/),,128.9,92640,DB00945,Acetylsalicylic acid
,18254152,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 179 --> 137, 137 --> 93 and 435 --> 319 for ASA, SA and IS, respectively.","Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254152/),,179,92858,DB00945,Acetylsalicylic acid
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,2,93414,DB00945,Acetylsalicylic acid
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.55,93415,DB00945,Acetylsalicylic acid
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.75,93416,DB00945,Acetylsalicylic acid
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,0.85,93417,DB00945,Acetylsalicylic acid
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,8.1,93777,DB00945,Acetylsalicylic acid
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,8. 6,93778,DB00945,Acetylsalicylic acid
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,3.5,93779,DB00945,Acetylsalicylic acid
,10849251,elimination half-life (t1/2),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,20.1,94701,DB00945,Acetylsalicylic acid
,10849251,area under the plasma concentration-time curve (AUC),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,637,94702,DB00945,Acetylsalicylic acid
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.14 +/- 0.05 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.14,94703,DB00945,Acetylsalicylic acid
,10849251,elimination half-life (t1/2),"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,22.2,94704,DB00945,Acetylsalicylic acid
,10849251,AUC,"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,3824.2,94705,DB00945,Acetylsalicylic acid
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.17 +/- 0. 01 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.17,94706,DB00945,Acetylsalicylic acid
,12877570,t1/2,"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),,43.1,95546,DB00945,Acetylsalicylic acid
,12877570,t1/2,"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),,31.2,95547,DB00945,Acetylsalicylic acid
,12877570,t1/2,"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),,27.3,95548,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],203.7,95549,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],261.1,95550,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],280.4,95551,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],100.1,95552,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],106.9,95553,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"In camels, sheep and goats given the drug i.v., the t1/2 values were 43.1, 31.2 and 27.3; the clearance (Cl) values were 203.7, 261.1, and 280.4 ml/h/kg, while the area under the curve (AUC) were 100.1, 106.9 and 110.5 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],110.5,95554,DB00945,Acetylsalicylic acid
,12877570,peak plasma concentration (Cmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[mg] / [ml],0.94,95555,DB00945,Acetylsalicylic acid
,12877570,peak plasma concentration (Cmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[mg] / [ml],1.44,95556,DB00945,Acetylsalicylic acid
,12877570,peak plasma concentration (Cmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[mg] / [ml],1.74,95557,DB00945,Acetylsalicylic acid
,12877570,time to reach Cmax (tmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),h,2.94,95558,DB00945,Acetylsalicylic acid
,12877570,time to reach Cmax (tmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),h,2.57,95559,DB00945,Acetylsalicylic acid
,12877570,time to reach Cmax (tmax),"In camels, sheep and goats given the drug by the i.m. route the mean peak plasma concentration (Cmax) were 0.94, 1.44 and 1.74 mg/ml, and the time to reach Cmax (tmax) were 2.94, 2.57 and 2.43h, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),h,2.43,95560,DB00945,Acetylsalicylic acid
,12877570,t1/2,"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),min,48.9,95561,DB00945,Acetylsalicylic acid
,12877570,t1/2,"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),min,38.2,95562,DB00945,Acetylsalicylic acid
,12877570,t1/2,"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),min,36.0,95563,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],261.3,95564,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],297.4,95565,DB00945,Acetylsalicylic acid
,12877570,clearance (Cl),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[ml] / [h·kg],306.4,95566,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],101.6,95567,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],117.3,95568,DB00945,Acetylsalicylic acid
,12877570,area under the curve (AUC),"The t1/2 values were 48.9, 38.2 and 36.0 min; the clearance (Cl) values were 261.3, 297.4 and 306.4 ml/h/kg, while the area under the curve (AUC) were 101.6, 117.3 and 123.7 mg.h/L, respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),[h·mg] / [l],123.7,95569,DB00945,Acetylsalicylic acid
,12877570,bioavailability (F),"The drug bioavailability (F) in camels, sheep and goats were 71.3, 78.4 and 79.4% respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),%,71.3,95570,DB00945,Acetylsalicylic acid
,12877570,bioavailability (F),"The drug bioavailability (F) in camels, sheep and goats were 71.3, 78.4 and 79.4% respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),%,78.4,95571,DB00945,Acetylsalicylic acid
,12877570,bioavailability (F),"The drug bioavailability (F) in camels, sheep and goats were 71.3, 78.4 and 79.4% respectively.","Comparative pharmacokinetics of salicylate in camels, sheep and goats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12877570/),%,79.4,95572,DB00945,Acetylsalicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],221,96093,DB00945,Acetylsalicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],191,96094,DB00945,Acetylsalicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],1323,96095,DB00945,Acetylsalicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],6000,96096,DB00945,Acetylsalicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,3.42,96097,DB00945,Acetylsalicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,3.02,96098,DB00945,Acetylsalicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,0.29,96099,DB00945,Acetylsalicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.38,96100,DB00945,Acetylsalicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.27,96101,DB00945,Acetylsalicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.68,96102,DB00945,Acetylsalicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],1.57,96103,DB00945,Acetylsalicylic acid
,3181281,terminal phase rate constant,The terminal phase rate constant ranged from 1.52 h-1 after intravenous injection to 1.88 h-1 after the oral modified release form.,"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),1/[h],1.52,96104,DB00945,Acetylsalicylic acid
,3181281,terminal phase rate constant,The terminal phase rate constant ranged from 1.52 h-1 after intravenous injection to 1.88 h-1 after the oral modified release form.,"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),1/[h],1.88,96105,DB00945,Acetylsalicylic acid
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.0,96562,DB00945,Acetylsalicylic acid
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.25,96563,DB00945,Acetylsalicylic acid
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,0.5,96564,DB00945,Acetylsalicylic acid
,1133735,retention time,"At best, about 40% of the dose (on the average) was absorbed when retention time in the bowel was limited to 2 hr.",Bioavailability of aspirin from commercial suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133735/),h,2,96960,DB00945,Acetylsalicylic acid
,713432,half-life,Elimination of acetylsalicylic acid was relatively quick within the first period after intravenous administration according to a half-life of 8 minutes.,Pharmacokinetic investigations in adult humans after parenteral administration of the lysine salt of acetyl-salicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/713432/),min,8,97339,DB00945,Acetylsalicylic acid
,713432,Half-life,Half-life of salicylic acid was determined to be 3 hours.,Pharmacokinetic investigations in adult humans after parenteral administration of the lysine salt of acetyl-salicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/713432/),h,3,97340,DB00945,Acetylsalicylic acid
,7503066,terminal half-life,"The mean (+/- SD) terminal half-life ranged from 2.1 +/- 1.0 hours in the 25 mg/kg DCLHb group to 4.3 +/- 1.4 hours in the 100 mg/kg group, but did not differ significantly between groups.",Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503066/),h,2.1,97885,DB00945,Acetylsalicylic acid
,7503066,terminal half-life,"The mean (+/- SD) terminal half-life ranged from 2.1 +/- 1.0 hours in the 25 mg/kg DCLHb group to 4.3 +/- 1.4 hours in the 100 mg/kg group, but did not differ significantly between groups.",Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503066/),h,4.3,97886,DB00945,Acetylsalicylic acid
,7503066,areas under the plasma concentration-time curves,"Mean baseline plasma hemoglobin corrected areas under the plasma concentration-time curves increased from 89 to 1,136 mg/hr/dL across the fourfold dose range.",Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503066/),[mg] / [dl·h],89,97887,DB00945,Acetylsalicylic acid
,7503066,areas under the plasma concentration-time curves,"Mean baseline plasma hemoglobin corrected areas under the plasma concentration-time curves increased from 89 to 1,136 mg/hr/dL across the fourfold dose range.",Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503066/),[mg] / [dl·h],1,97888,DB00945,Acetylsalicylic acid
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,45,101536,DB00945,Acetylsalicylic acid
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,42,101537,DB00945,Acetylsalicylic acid
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],2.6,101538,DB00945,Acetylsalicylic acid
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],12.4,101539,DB00945,Acetylsalicylic acid
,7736686,terminal phase elimination half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase elimination half-life of conventional immediate release flurbiprofen (3 to 6 hours).",Clinical pharmacokinetics of flurbiprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736686/),h,3 to 6,102250,DB00945,Acetylsalicylic acid
more,1904550,Peak plasma levels,"Peak plasma levels of more than 10(-4) M have been reported (Forrest et al., 1982) and 2 groups of investigators (Kocisova et al., 1988; Hongslo et al., 1990) found PCM to be weakly clastogenic in human lymphocytes in vivo in the maximum human therapeutic dose range.",Further investigations on the clastogenicity of paracetamol and acetylsalicylic acid in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904550/),M,10(-4),102685,DB00945,Acetylsalicylic acid
,11273013,Systemic clearance,"Systemic clearance of DCLHb was estimated to be 2.2 +/- 0.7 mL h(-1) in the treatment group and was slightly, but not significantly, less in the control group (3.6 +/- 1.7 mL h(-1)).",Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273013/),[ml] / [h],2.2,103012,DB00945,Acetylsalicylic acid
,11273013,Systemic clearance,"Systemic clearance of DCLHb was estimated to be 2.2 +/- 0.7 mL h(-1) in the treatment group and was slightly, but not significantly, less in the control group (3.6 +/- 1.7 mL h(-1)).",Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273013/),[ml] / [h],3.6,103013,DB00945,Acetylsalicylic acid
,11273013,elimination half-life,"There was also a trend toward a longer elimination half-life in the treatment group (4.7 +/- 2.2 h) compared with the control group (3.8 +/- 0.8 h), although this difference was not statistically significant.",Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273013/),h,4.7,103014,DB00945,Acetylsalicylic acid
,11273013,elimination half-life,"There was also a trend toward a longer elimination half-life in the treatment group (4.7 +/- 2.2 h) compared with the control group (3.8 +/- 0.8 h), although this difference was not statistically significant.",Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273013/),h,3.8,103015,DB00945,Acetylsalicylic acid
,17610403,V(d(ss)),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[l] / [kg],0.18,103021,DB00945,Acetylsalicylic acid
,17610403,Cl(B),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[ml] / [kg·min],3.36,103022,DB00945,Acetylsalicylic acid
,17610403,t(1/2 lambda),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),h,0.63,103023,DB00945,Acetylsalicylic acid
<,17610403,Peak salicylate concentrations,Peak salicylate concentrations following oral aspirin administration was <10 microg/mL and failed to attenuate cortisol response.,Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[μg] / [ml],10,103024,DB00945,Acetylsalicylic acid
,7355969,Cp,"Using this equation, we calculated Cp = 0.57 +/- 0.12 ml/min . kg and Cf = 1.93 +/- 0.22 ml/min .",The placental transfer of acetylsalicylic acid in near-term ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7355969/),[ml] / [kg·min],0.57,103375,DB00945,Acetylsalicylic acid
,7355969,Cf,"Using this equation, we calculated Cp = 0.57 +/- 0.12 ml/min . kg and Cf = 1.93 +/- 0.22 ml/min .",The placental transfer of acetylsalicylic acid in near-term ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7355969/),[ml] / [min],1.93,103376,DB00945,Acetylsalicylic acid
,14716871,relative bioavailability,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),%,105.36,103520,DB00945,Acetylsalicylic acid
,14716871,AUC0-T,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[h·μg] / [ml],103.10,103521,DB00945,Acetylsalicylic acid
,14716871,AUC0-T,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[h·μg] / [ml],98.45,103522,DB00945,Acetylsalicylic acid
,14716871,Tmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),h,1.5,103523,DB00945,Acetylsalicylic acid
,14716871,Cmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[μg] / [ml],19.31,103524,DB00945,Acetylsalicylic acid
,14716871,Cmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[μg] / [ml],18.95,103525,DB00945,Acetylsalicylic acid
,6861813,plasma half life,"Following single oral doses of 10 to 100 mg, piroxicam is rapidly and fully absorbed, and eliminated with a mean plasma half life of about 45 hr.",Pharmacokinetics of piroxicam in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),h,45,105048,DB00945,Acetylsalicylic acid
,6861813,peak concentrations,Mean peak concentrations are about 2 micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state with 20 mg daily.,Pharmacokinetics of piroxicam in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),[μg] / [ml],2,105049,DB00945,Acetylsalicylic acid
,6861813,peak concentrations,Mean peak concentrations are about 2 micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state with 20 mg daily.,Pharmacokinetics of piroxicam in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861813/),[μg] / [ml],6,105050,DB00945,Acetylsalicylic acid
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,249,106087,DB00945,Acetylsalicylic acid
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,950,106088,DB00945,Acetylsalicylic acid
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,834,106089,DB00945,Acetylsalicylic acid
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,286,106090,DB00945,Acetylsalicylic acid
over,9521569,recovery,A linear response to quantities of ASA from 0.1 to 100 microg/cm2 and of SA from 0.1 to 5 microg/cm2 in tape and to quantities of ASA 0.1 to 2 microg/ml and 1 to 50 microg/ml was obtained and the recovery from tape and plasma samples was over 98%.,Determination of acetylsalicylic acid and salicylic acid in skin and plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521569/),%,98,107314,DB00945,Acetylsalicylic acid
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,3.0,108999,DB00945,Acetylsalicylic acid
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,1.2,109000,DB00945,Acetylsalicylic acid
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,less,109001,DB00945,Acetylsalicylic acid
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,100,109002,DB00945,Acetylsalicylic acid
,22674769,flow rate,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),[ml] / [min],0.8,110441,DB00945,Acetylsalicylic acid
,22674769,total run time,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),min,2.2,110442,DB00945,Acetylsalicylic acid
,10468077,t 50%,"For example, the t 50% for serum TxB2 inhibition was 5.0 +/- 0.6 minutes with the chewed tablet versus 12.0 +/- 2.3 minutes when the tablet was swallowed (p = 0.01).",Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468077/),min,5.0,113145,DB00945,Acetylsalicylic acid
,10468077,t 50%,"For example, the t 50% for serum TxB2 inhibition was 5.0 +/- 0.6 minutes with the chewed tablet versus 12.0 +/- 2.3 minutes when the tablet was swallowed (p = 0.01).",Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468077/),min,12.0,113146,DB00945,Acetylsalicylic acid
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],159,113220,DB00945,Acetylsalicylic acid
,657721,peak codeine plasma concentrations,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],138,113221,DB00945,Acetylsalicylic acid
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.9,113222,DB00945,Acetylsalicylic acid
,657721,beta-phase elimination half-lives,"Following administration of codeine phosphate (60 mg) in combination with aspirin (650 mg) or acetaminophen (600 mg) to two separate groups, mean peak codeine plasma concentrations and beta-phase elimination half-lives were 159 ng/ml and 2.9 hr or 138 ng/ml and 2.4 hr, respectively.",Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),h,2.4,113223,DB00945,Acetylsalicylic acid
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],6.8,113224,DB00945,Acetylsalicylic acid
,657721,maximum concentrations,Mean maximum concentrations of metabolically produced morphine were 6.8 ng/ml (aspirin-codeine phosphate administration) and 7.4 ng/ml (acetaminophen-codeine phosphate).,Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657721/),[ng] / [ml],7.4,113225,DB00945,Acetylsalicylic acid
,6342955,half-life,"Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days.",Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342955/),h,50,114992,DB00945,Acetylsalicylic acid
,8055680,terminal elimination half-life,The terminal elimination half-life is between 20 and 50 hours.,Clinical pharmacokinetics of ticlopidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8055680/),h,20 and 50,118182,DB00945,Acetylsalicylic acid
,8419064,total run time,"HPLC 1 allows quantification of 5MTHF by absorption at 313 nm; HPLC 2, the quantification of l-FA and d-FA by electrochemical detection in the oxidation mode (total run time 18 min).",HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),min,18,119499,DB00945,Acetylsalicylic acid
>,8419064,Recoveries,Recoveries are > 80%.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),%,80,119500,DB00945,Acetylsalicylic acid
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),[nM] / [l],50,119501,DB00945,Acetylsalicylic acid
,8419064,sensitivity,The sensitivity limit is 50 nmol/L for 5MTHF and 20 nmol/L for l-FA and d-FA.,HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419064/),,20,119502,DB00945,Acetylsalicylic acid
,16390350,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 40.2 l per 70 kg.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·kg],40.2,120128,DB00945,Acetylsalicylic acid
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.486,120129,DB00945,Acetylsalicylic acid
,16390350,Clearance (CL),Clearance (CL) increased from 0.486 l h(-1) per 70 kg at 24 weeks PCA to 0.940 l h(-1) per 70 kg by 30 weeks PCA.,Limited predictability of amikacin clearance in extreme premature neonates at birth. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390350/),[l] / [70·h·kg],0.940,120130,DB00945,Acetylsalicylic acid
,1370924,Steady-state plasma iloprost concentration,Steady-state plasma iloprost concentration was 591 +/- 64 pmol/l.,Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[pM] / [l],591,120742,DB00945,Acetylsalicylic acid
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],454,120743,DB00945,Acetylsalicylic acid
,1370924,Steady-state clearance,"Steady-state clearance of t-PA was unchanged by iloprost (454 +/- 65 versus 443 +/- 136 ml/min in controls, p = NS).",Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1370924/),[ml] / [min],443,120744,DB00945,Acetylsalicylic acid
,14671681,relative bioavailability,"Furthermore, a relative bioavailability of approximately 100% of the preliminary formulation was shown for the newly developed formulation for all parameters.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),%,100,122142,DB00945,Acetylsalicylic acid
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],1040.66,122143,DB00945,Acetylsalicylic acid
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],142.28,122144,DB00945,Acetylsalicylic acid
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],134.52,122145,DB00945,Acetylsalicylic acid
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],30.34,122146,DB00945,Acetylsalicylic acid
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.67,122147,DB00945,Acetylsalicylic acid
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.92,122148,DB00945,Acetylsalicylic acid
,15206991,IC50,"There was a dose-dependent blockade of TxA2 receptors and of inhibition of thromboxane synthase activity with values for IC50 of 12 ng ml(-1) and 6.7 ng ml(-1), respectively.","Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206991/),[ng] / [ml],12,122654,DB00945,Acetylsalicylic acid
,15206991,IC50,"There was a dose-dependent blockade of TxA2 receptors and of inhibition of thromboxane synthase activity with values for IC50 of 12 ng ml(-1) and 6.7 ng ml(-1), respectively.","Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15206991/),[ng] / [ml],6.7,122655,DB00945,Acetylsalicylic acid
,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],1.3,123772,DB00945,Acetylsalicylic acid
>,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],289,123773,DB00945,Acetylsalicylic acid
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],21,123774,DB00945,Acetylsalicylic acid
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.024,123775,DB00945,Acetylsalicylic acid
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.52,123776,DB00945,Acetylsalicylic acid
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.57,123777,DB00945,Acetylsalicylic acid
,3203708,elimination half-life,"The study showed that: 1. OLZ had a very short elimination half-life, mean 56 min.",The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203708/),min,56,125197,DB00945,Acetylsalicylic acid
,3203708,serum half-life,Following the i.v. dose the serum half-life of the O-sulphate was estimated to be 7 days.,The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203708/),d,7,125198,DB00945,Acetylsalicylic acid
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,36,126959,DB00945,Acetylsalicylic acid
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,60,126960,DB00945,Acetylsalicylic acid
,6825385,bioavailability,During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01).,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,24,126961,DB00945,Acetylsalicylic acid
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],511,126962,DB00945,Acetylsalicylic acid
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],344,126963,DB00945,Acetylsalicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[μg] / [ml],640.0,127345,DB00945,Acetylsalicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[ng] / [mg],446.0,127346,DB00945,Acetylsalicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[ng] / [mg],281.3,127347,DB00945,Acetylsalicylic acid
,3802700,GRT,The mean (+/- SD) GRT was significantly delayed by food (0.8 +/- 0.5 vs. 5.9 +/- 3.3 hours; P less than 0.005).,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),h,0.8,129962,DB00945,Acetylsalicylic acid
,3802700,GRT,The mean (+/- SD) GRT was significantly delayed by food (0.8 +/- 0.5 vs. 5.9 +/- 3.3 hours; P less than 0.005).,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),h,5.9,129963,DB00945,Acetylsalicylic acid
,3802700,lag time (TL),The mean (+/- SD) lag time (TL) and time to peak concentration (expressed as salicylic acid equivalents) were markedly prolonged after the fed regimen (2.7 +/- 0.8 vs.,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),,2.7,129964,DB00945,Acetylsalicylic acid
,11888331,terminal elimination half-life,"The drug binds to plasma proteins (>99%), predominantly to albumin, and has a mean terminal elimination half-life of approximately 10 hours in both healthy volunteers and patients with asthma.",Pharmacokinetic profile of zafirlukast. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888331/),h,10,132702,DB00945,Acetylsalicylic acid
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],1,132975,DB00945,Acetylsalicylic acid
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],15,132976,DB00945,Acetylsalicylic acid
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB00945,Acetylsalicylic acid
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB00945,Acetylsalicylic acid
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB00945,Acetylsalicylic acid
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB00945,Acetylsalicylic acid
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB00945,Acetylsalicylic acid
,28556061,TXB2,Baseline TXB2 levels were median 0·35 ng/mL (0·07-0·94).,Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28556061/),[ng] / [ml],0·35,135682,DB00945,Acetylsalicylic acid
less,3552584,Volume of distribution,Volume of distribution is mostly low (less than 0.2 L/kg) and protein binding is high (usually 95 to 99%).,Non-steroidal anti-inflammatory analgesics other than salicylates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),[l] / [kg],0.2,136228,DB00945,Acetylsalicylic acid
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,2 to 5,136229,DB00945,Acetylsalicylic acid
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,20,136230,DB00945,Acetylsalicylic acid
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,10,136231,DB00945,Acetylsalicylic acid
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,12-15,136232,DB00945,Acetylsalicylic acid
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,16,136233,DB00945,Acetylsalicylic acid
,3552584,half-life,"Piroxicam has the longest half-life, averaging 45 hours.",Non-steroidal anti-inflammatory analgesics other than salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,45,136234,DB00945,Acetylsalicylic acid
,15951475,relative bioavailability,DP relative bioavailability was reduced 53% with conventional tablets compared to the composite buffered ER capsule in reduced gastric acid conditions.,Dipyridamole bioavailability in subjects with reduced gastric acidity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951475/),%,53,136569,DB00945,Acetylsalicylic acid
,19262071,area under the,"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [h·ml],136,136582,DB00945,Acetylsalicylic acid
,19262071,area under the,"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [h·ml],94,136583,DB00945,Acetylsalicylic acid
,19262071,C(max),"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [ml],23,136584,DB00945,Acetylsalicylic acid
,19262071,C(max),"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [ml],17,136585,DB00945,Acetylsalicylic acid
,2757664,absolute bioavailability,The investigations led to the following results: The absolute bioavailability of the test formulation was 95%.,[Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757664/),%,95,138778,DB00945,Acetylsalicylic acid
,2757664,maximal concentration,The maximal concentration of SA after intravenous administration of the standard formulation was reached after 0.4 h on an average and amounted to 62 micrograms/ml.,[Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757664/),[μg] / [ml],62,138779,DB00945,Acetylsalicylic acid
,2757664,concentration maximum,"After oral administration of the test formulation, a mean concentration maximum of 28 micrograms/ml was calculated, which had been reached after about 2 h.",[Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757664/),[μg] / [ml],28,138780,DB00945,Acetylsalicylic acid
,2757664,time for SA,"The mean time for SA was 6 h after the standard formulation, whereas after administration of the test compound, a mean of 11.5 h was calculated.",[Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757664/),h,6,138781,DB00945,Acetylsalicylic acid
,2757664,time for SA,"The mean time for SA was 6 h after the standard formulation, whereas after administration of the test compound, a mean of 11.5 h was calculated.",[Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757664/),h,11.5,138782,DB00945,Acetylsalicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],8.88,139795,DB00945,Acetylsalicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],42.6,139796,DB00945,Acetylsalicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],10.1,139797,DB00945,Acetylsalicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,11.2,139798,DB00945,Acetylsalicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,23.7,139799,DB00945,Acetylsalicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,28.6,139800,DB00945,Acetylsalicylic acid
,17763375,t(1/2),Atenolol aspirinate was stable towards aqueous hydrolysis but rapidly hydrolyzed in plasma (t(1/2) = 7.6 min).,Pharmacokinetic profile of atenolol aspirinate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763375/),min,7.6,140392,DB00945,Acetylsalicylic acid
,6859071,accumulation,"After intraperitoneal administration, salicylate levels in rabbit plasma, similar to those of humans receiving four to six aspirin tablets (325 mg each), result in accumulation of salicylate by lens (mean +/- SD) of 405 +/- 72 mumoles/g and 620 +/- 30 mumoles/g at two and four hours, respectively.",Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859071/),[mumoles] / [g],405,140922,DB00945,Acetylsalicylic acid
,6859071,accumulation,"After intraperitoneal administration, salicylate levels in rabbit plasma, similar to those of humans receiving four to six aspirin tablets (325 mg each), result in accumulation of salicylate by lens (mean +/- SD) of 405 +/- 72 mumoles/g and 620 +/- 30 mumoles/g at two and four hours, respectively.",Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859071/),[mumoles] / [g],620,140923,DB00945,Acetylsalicylic acid
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.48,143245,DB00945,Acetylsalicylic acid
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.52,143246,DB00945,Acetylsalicylic acid
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.47,143247,DB00945,Acetylsalicylic acid
,1777842,maximum concentration,"Ten minutes after administration of I, aspirin reached a maximum concentration of 12.9 micrograms/mL, while salicylamide concentration reached a peak value of 3.4 micrograms/mL.",Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777842/),[μg] / [ml],12.9,143755,DB00945,Acetylsalicylic acid
,1777842,peak value,"Ten minutes after administration of I, aspirin reached a maximum concentration of 12.9 micrograms/mL, while salicylamide concentration reached a peak value of 3.4 micrograms/mL.",Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777842/),[μg] / [ml],3.4,143756,DB00945,Acetylsalicylic acid
,33990657,Vmax,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,6.5,145779,DB00945,Acetylsalicylic acid
,33990657,Km,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,147.5,145780,DB00945,Acetylsalicylic acid
,33990657,Vmax,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,108.1,145781,DB00945,Acetylsalicylic acid
,33990657,Km,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,803.2,145782,DB00945,Acetylsalicylic acid
,33990657,tmax,"After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),h,3 and 6,145783,DB00945,Acetylsalicylic acid
,33990657,tmax,"After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),h,0.5 and 1.0,145784,DB00945,Acetylsalicylic acid
,33990657,Plasma AUC,"Plasma AUC was 725.5 (89.8-1222) for EC-ASA, and 823.1(624-1196) ng h/mL (median, 25-75% CI) for plain ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),[h·ng] / [ml],725.5,145785,DB00945,Acetylsalicylic acid
,33990657,Plasma AUC,"Plasma AUC was 725.5 (89.8-1222) for EC-ASA, and 823.1(624-1196) ng h/mL (median, 25-75% CI) for plain ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),[h·ng] / [ml],823.1,145786,DB00945,Acetylsalicylic acid
,22287037,onset,"For first perceptible relief, FR-aspirin onset was 19.8 and 16.3 min for 650 mg and 1,000 mg, respectively, compared to 23.7 and 20.0 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,19.8,150921,DB00945,Acetylsalicylic acid
,22287037,onset,"For first perceptible relief, FR-aspirin onset was 19.8 and 16.3 min for 650 mg and 1,000 mg, respectively, compared to 23.7 and 20.0 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,16.3,150922,DB00945,Acetylsalicylic acid
,22287037,onset,"For first perceptible relief, FR-aspirin onset was 19.8 and 16.3 min for 650 mg and 1,000 mg, respectively, compared to 23.7 and 20.0 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,23.7,150923,DB00945,Acetylsalicylic acid
,22287037,onset,"For first perceptible relief, FR-aspirin onset was 19.8 and 16.3 min for 650 mg and 1,000 mg, respectively, compared to 23.7 and 20.0 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,20.0,150924,DB00945,Acetylsalicylic acid
,22287037,FR,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,48.9,150925,DB00945,Acetylsalicylic acid
,22287037,FR,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,49.4,150926,DB00945,Acetylsalicylic acid
,22287037,FR,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,119.2,150927,DB00945,Acetylsalicylic acid
,22287037,FR,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,99.2,150928,DB00945,Acetylsalicylic acid
,22287037,onset,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,48.9,150929,DB00945,Acetylsalicylic acid
,22287037,onset,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),min,49.4,150930,DB00945,Acetylsalicylic acid
,22287037,onset,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,119.2,150931,DB00945,Acetylsalicylic acid
,22287037,onset,"For meaningful relief, FR-aspirin onset was 48.9 and 49.4 min for 650 mg and 1,000 mg, respectively, compared to 119.2 and 99.2 for R-aspirin.",Evaluation of onset of pain relief from micronized aspirin in a dental pain model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22287037/),,99.2,150932,DB00945,Acetylsalicylic acid
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[μg] / [l],10,152142,DB00945,Acetylsalicylic acid
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[mg] / [l],0.5,152143,DB00945,Acetylsalicylic acid
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"1,3",155977,DB00945,Acetylsalicylic acid
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"2,1",155978,DB00945,Acetylsalicylic acid
,25406385,apparent elimination half-life,"Urinary alkalization was not attempted during the first admission, which was associated with the longest apparent elimination half-life of salicylate (30 hours).",Multiple episodes of aspirin overdose in an individual patient: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406385/),h,30,156753,DB00945,Acetylsalicylic acid
,25998572,half-life,"ASA acetylates cyclooxygenase in the portal circulation and is rapidly (half-life, 20 min) hydrolyzed.",A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998572/),min,20,158883,DB00945,Acetylsalicylic acid
,10537230,bioavailability,"With a single administration of 300 mg/kg of the extract, aspirin blood levels were undetectable while salicylic acid bioavailability was reduced in 59%.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,59,159422,DB00945,Acetylsalicylic acid
,10537230,bioavailability,"Chronic administration once daily for 4 weeks of 100 and 300 mg/kg of the extract resulted in undetectable aspirin blood levels, while salicylic acid bioavailability was reduced in 63 and 76%, respectively, compared with controls.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,63,159423,DB00945,Acetylsalicylic acid
,10537230,bioavailability,"Chronic administration once daily for 4 weeks of 100 and 300 mg/kg of the extract resulted in undetectable aspirin blood levels, while salicylic acid bioavailability was reduced in 63 and 76%, respectively, compared with controls.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,76,159424,DB00945,Acetylsalicylic acid
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,55,159497,DB00945,Acetylsalicylic acid
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,66,159498,DB00945,Acetylsalicylic acid
,6500763,Plasma protein binding,Plasma protein binding of isofezolac was very high (99%) and did not influence salicylic acid binding.,The effect of antacid and aspirin on the bioavailability of isofezolac in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500763/),%,99,159966,DB00945,Acetylsalicylic acid
,19805643,excretion,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[nM] / [24·h],52,160613,DB00945,Acetylsalicylic acid
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.25,160614,DB00945,Acetylsalicylic acid
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.22,160615,DB00945,Acetylsalicylic acid
,22465277,area under the concentration time curve (AUC),"The pharmacokinetic data demonstrate that the area under the concentration time curve (AUC) of the aspirin was 2031 ± 266 min μg/mL after aspirin administration (100mg/kg, i.v.).",Simultaneous determination and pharmacokinetics of protein unbound aspirin and salicylic acid in rat blood and brain by microdialysis: an application to herbal-drug interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465277/),[min·μg] / [ml],2031,165126,DB00945,Acetylsalicylic acid
,22465277,AUC,"The AUC of salicylic acid was 12660 ± 1799 min μg/mL, which suggests that aspirin is quickly hydrolyzed to salicylic acid in blood and the metabolite can also be detected within 15 min in brain dialysate.",Simultaneous determination and pharmacokinetics of protein unbound aspirin and salicylic acid in rat blood and brain by microdialysis: an application to herbal-drug interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465277/),[min·μg] / [ml],12660,165127,DB00945,Acetylsalicylic acid
,8573422,absolute bioavailability,An absolute bioavailability of approximately 6% has been reported with large inter- and intra-subject variability.,Human pharmacokinetics of tiludronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),%,6,165181,DB00945,Acetylsalicylic acid
,8573422,elimination half-life,"The elimination half-life in patients with normal renal function is approximately 40-60 h, but is significantly increased in subjects with severe renal impairment.",Human pharmacokinetics of tiludronate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),h,40-60,165182,DB00945,Acetylsalicylic acid
,8573422,renal clearance,The renal clearance (0.7 L/h) is independent of dose and suggests that glomerular filtration is the mechanism responsible for elimination.,Human pharmacokinetics of tiludronate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573422/),[l] / [h],0.7,165183,DB00945,Acetylsalicylic acid
,7094976,time until 50%,"The median time until 50% and 90% were emptied from the stomach was 1 and 3-3.5 h, respectively, for both the uncoated and enteric-coated granules.",Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094976/),h,1,165412,DB00945,Acetylsalicylic acid
,7094976,time until 50%,"The median time until 50% and 90% were emptied from the stomach was 1 and 3-3.5 h, respectively, for both the uncoated and enteric-coated granules.",Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094976/),h,3-3.5,165413,DB00945,Acetylsalicylic acid
,25586152,time to reach maximum plasma concentration [t max],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,22.50,165439,DB00945,Acetylsalicylic acid
,25586152,elimination half-life [t ½],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,21.70,165440,DB00945,Acetylsalicylic acid
,25586152,maximum plasma concentration (C max),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[pg] / [ml],2.56,165441,DB00945,Acetylsalicylic acid
,25586152,area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[min·pg] / [ml],70.68,165442,DB00945,Acetylsalicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166074,DB00945,Acetylsalicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166075,DB00945,Acetylsalicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166076,DB00945,Acetylsalicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166077,DB00945,Acetylsalicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166078,DB00945,Acetylsalicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166079,DB00945,Acetylsalicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166080,DB00945,Acetylsalicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166081,DB00945,Acetylsalicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,33.9,166082,DB00945,Acetylsalicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,23.9,166083,DB00945,Acetylsalicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,33.6,166084,DB00945,Acetylsalicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,22.6,166085,DB00945,Acetylsalicylic acid
,21696537,area under the,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,54,166599,DB00945,Acetylsalicylic acid
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,66.3,166600,DB00945,Acetylsalicylic acid
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,47,166601,DB00945,Acetylsalicylic acid
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,59.7,166602,DB00945,Acetylsalicylic acid
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,68.9,166603,DB00945,Acetylsalicylic acid
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,64.5,166604,DB00945,Acetylsalicylic acid
,7328486,bioavailability,The bioavailability of aspirin from an aspirin aluminum tablet was nearly 60% of that from an aspirin tablet.,The bioavailabilities of aspirin from an aspirin aluminum and an aspirin tablet and the effects of food and aluminum hydroxide gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7328486/),%,60,170172,DB00945,Acetylsalicylic acid
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,175,171056,DB00945,Acetylsalicylic acid
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,72,171057,DB00945,Acetylsalicylic acid
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,65,171058,DB00945,Acetylsalicylic acid
,6776176,half-life,"However, unexpectedly, the half-life of the drug in this patient was twice as long (7.5 hours) as that found in six previous studies (3.7 hours) of elderly patients given similar doses.",Aspirin absorption from a feeding jejunostomy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6776176/),h,7.5,171204,DB00945,Acetylsalicylic acid
,6776176,half-life,"However, unexpectedly, the half-life of the drug in this patient was twice as long (7.5 hours) as that found in six previous studies (3.7 hours) of elderly patients given similar doses.",Aspirin absorption from a feeding jejunostomy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6776176/),h,3.7,171205,DB00945,Acetylsalicylic acid
greater,2547464,time to reach peak plasma concentration (tmax,"Sodium bicarbonate given together and 30 min after diflunisal tablets significantly (p less than 0.05) shortened the time to reach peak plasma concentration (tmax greater than 15 per cent), raised maximum plasma concentration slightly (Cmax 6 per cent) and increased the area under the plasma concentration-time curve (AUC greater than 8 per cent).",Buffering the stomach content enhances the absorption of diflunisal in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,15,171847,DB00945,Acetylsalicylic acid
greater,2547464,area under the plasma concentration-time curve (AUC,"Sodium bicarbonate given together and 30 min after diflunisal tablets significantly (p less than 0.05) shortened the time to reach peak plasma concentration (tmax greater than 15 per cent), raised maximum plasma concentration slightly (Cmax 6 per cent) and increased the area under the plasma concentration-time curve (AUC greater than 8 per cent).",Buffering the stomach content enhances the absorption of diflunisal in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),-1,8,171848,DB00945,Acetylsalicylic acid
,2547464,terminal half-life,"In one volunteer, after intravenous administration diflunisal plasma concentrations declined in a triphasic manner with a terminal half-life of 12.8 h.",Buffering the stomach content enhances the absorption of diflunisal in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),h,12.8,171849,DB00945,Acetylsalicylic acid
,2547464,volume of distribution,The volume of distribution was approximately 10 per cent of body weight.,Buffering the stomach content enhances the absorption of diflunisal in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,10,171850,DB00945,Acetylsalicylic acid
,2547464,absolute bioavailability,"Based on the ratio of AUC after equivalent i.v. and oral diflunisal doses, the absolute bioavailability was 89.5 per cent.",Buffering the stomach content enhances the absorption of diflunisal in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,89.5,171851,DB00945,Acetylsalicylic acid
,7249487,peak plasma concentrations,"In general, peak plasma concentrations of 2 to 3 microgram/ml are achieved with 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed.",Clinical Pharmacokinetics of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[μg] / [ml],2 to 3,172594,DB00945,Acetylsalicylic acid
,7249487,biological half-life,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),h,5 to 10,172595,DB00945,Acetylsalicylic acid
,7249487,plasma clearance,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[ml] / [kg·min],1 to 2.5,172596,DB00945,Acetylsalicylic acid
,504040,peak blood levels,Oral doses of 250 mg given to normal human volunteers provided peak blood levels of 10--11 micrograms/ml at 3--4 hours after administration.,"Tienilic acid: pharmacokinetics, salicylate interaction and creatinine secretion studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/504040/),[μg] / [ml],10--11,173162,DB00945,Acetylsalicylic acid
,31192749,V/F,"Finally, a new model applicable to our real-world dataset was established as follows: CL/F = 22.9 × (WT/70)0.75 × (1 - WZ × 0.264) × (1 - FCZ × 0.338) × (1 + ASPI × 0.281) × (POD/41)0.0486 L/h; V/F = 906 × (WT/70) L. Where WT, WZ, FCZ, ASPI and POD were weight, Wuzhi capsule, fluconazole, aspirin and post-transplantation day, respectively.",Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31192749/),,90,174531,DB00945,Acetylsalicylic acid
,2758104,area under curve,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),[μg] / [hml],5.09,177623,DB00945,Acetylsalicylic acid
,2758104,area under curve,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),[μg] / [hml],5.78,177624,DB00945,Acetylsalicylic acid
,2758104,time,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),h,0.45,177625,DB00945,Acetylsalicylic acid
,2758104,time,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),h,0.70,177626,DB00945,Acetylsalicylic acid
,7486364,peak salicylate concentrations,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg] / [dl],47.4,178070,DB00945,Acetylsalicylic acid
,7486364,peak salicylate concentrations,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg] / [dl],48.4,178071,DB00945,Acetylsalicylic acid
,7486364,areas under the time-serum salicylate concentration curve over 6 hours,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg·min] / [l],"171,000",178072,DB00945,Acetylsalicylic acid
,7486364,areas under the time-serum salicylate concentration curve over 6 hours,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),mg,"188,000",178073,DB00945,Acetylsalicylic acid
,2510140,clearance,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),[ml] / [kg·min],12.2,182118,DB00945,Acetylsalicylic acid
,2510140,steady-state volume of distribution,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),[l] / [kg],0.219,182119,DB00945,Acetylsalicylic acid
,2510140,terminal half-life,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,15.4,182120,DB00945,Acetylsalicylic acid
,2510140,mean absorption times,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,16.4,182121,DB00945,Acetylsalicylic acid
,2510140,mean absorption times,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,21.3,182122,DB00945,Acetylsalicylic acid
,2510140,bioavailability,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),%,54,182123,DB00945,Acetylsalicylic acid
,2510140,mean absorption time,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,97,182124,DB00945,Acetylsalicylic acid
,2510140,mean absorption time,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,53,182125,DB00945,Acetylsalicylic acid
,2510140,bioavailability,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),%,89,182126,DB00945,Acetylsalicylic acid
,22271472,overall survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,15.3,183279,DB00945,Acetylsalicylic acid
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.4,183280,DB00945,Acetylsalicylic acid
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183281,DB00945,Acetylsalicylic acid
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,16.0,183282,DB00945,Acetylsalicylic acid
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183283,DB00945,Acetylsalicylic acid
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183284,DB00945,Acetylsalicylic acid
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183285,DB00945,Acetylsalicylic acid
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183286,DB00945,Acetylsalicylic acid
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183287,DB00945,Acetylsalicylic acid
,29404053,flow rate,"n-Hexane (containing 0.1% acetic acid) and ethanol (75:25, v/v) were used as mobile phase at a flow rate of 0.6 mL/min.",Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),[ml] / [min],0.6,186144,DB00945,Acetylsalicylic acid
higher,29404053,extraction recovery,The average extraction recovery was higher than 85% for both enantiomers at QC levels.,Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),%,85,186145,DB00945,Acetylsalicylic acid
,8882301,protein binding to serum albumin,A mean protein binding to serum albumin of 42 to 57% is usually reported.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),%,42 to 57,186895,DB00945,Acetylsalicylic acid
,8882301,steady-state volume of distribution,The steady-state volume of distribution is approximately 1 L/kg.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [kg],1,186896,DB00945,Acetylsalicylic acid
,8882301,elimination half-life,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),h,5 to 8,186897,DB00945,Acetylsalicylic acid
,8882301,total body clearance,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [h],4.8 to 7.8,186898,DB00945,Acetylsalicylic acid
,22224124,peaks,"Mean peaks were 10.4, 11.3, and 12.2 mg/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg] / [dl],10.4,187157,DB00945,Acetylsalicylic acid
,22224124,peaks,"Mean peaks were 10.4, 11.3, and 12.2 mg/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg] / [dl],11.3,187158,DB00945,Acetylsalicylic acid
,22224124,peaks,"Mean peaks were 10.4, 11.3, and 12.2 mg/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg] / [dl],12.2,187159,DB00945,Acetylsalicylic acid
,22224124,area under the time concentration,"Mean area under the time concentration was 1,153, 1,401, and 1,743 mg-min/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg-min] / [dl],"1,153",187160,DB00945,Acetylsalicylic acid
,22224124,area under the time concentration,"Mean area under the time concentration was 1,153, 1,401, and 1,743 mg-min/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg-min] / [dl],"1,401",187161,DB00945,Acetylsalicylic acid
,22224124,area under the time concentration,"Mean area under the time concentration was 1,153, 1,401, and 1,743 mg-min/dL in groups 1, 2, and 3, respectively.",Comparison of three aspirin formulations in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224124/),[mg-min] / [dl],"1,743",187162,DB00945,Acetylsalicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.8,187238,DB00945,Acetylsalicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.7,187239,DB00945,Acetylsalicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.5,187240,DB00945,Acetylsalicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],13.4,187241,DB00945,Acetylsalicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],11.0,187242,DB00945,Acetylsalicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],6.6,187243,DB00945,Acetylsalicylic acid
,2584317,limit of detection,The limit of detection of the two assays was also similar at 0.01 microM.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),μM,0.01,187584,DB00945,Acetylsalicylic acid
,2584317,half-life,The 7-hydroxymethotrexate half-life was 15 h.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),h,15,187585,DB00945,Acetylsalicylic acid
,11599656,Peak serum levels,"Peak serum levels of salicylic acid were on average 1.2 mg/l, and the observed area under the serum concentration time curve (AUC) of salicylic acid was equivalent to that expected from an intake of 87 mg acetylsalicylic acid.",Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599656/),[mg] / [l],1.2,188852,DB00945,Acetylsalicylic acid
,7955799,plasma clearance,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),[ml] / [min],329,190673,DB00945,Acetylsalicylic acid
,7955799,steady-state volume of distribution,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),l,76,190674,DB00945,Acetylsalicylic acid
,7955799,half-life,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),h,1.6,190675,DB00945,Acetylsalicylic acid
,7955799,percentage of,The percentage of dose excreted in the urine was 37%.,"Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),%,37,190676,DB00945,Acetylsalicylic acid
,7955799,plasma concentration yielding 50% inhibition (C50),"The plasma concentration yielding 50% inhibition (C50) for MK-383 in healthy volunteers is approximately 13 ng/ml, with a Hill coefficient > 5.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),[ng] / [ml],13,190677,DB00945,Acetylsalicylic acid
>,7955799,Hill coefficient,"The plasma concentration yielding 50% inhibition (C50) for MK-383 in healthy volunteers is approximately 13 ng/ml, with a Hill coefficient > 5.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),,5,190678,DB00945,Acetylsalicylic acid
,23615159,baseline,Mean baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes.,"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23615159/),min,4.72 to 6.13,192647,DB00945,Acetylsalicylic acid
,23615159,BT,Mean baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes.,"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23615159/),min,4.72 to 6.13,192648,DB00945,Acetylsalicylic acid
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,31,195243,DB00945,Acetylsalicylic acid
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,25,195244,DB00945,Acetylsalicylic acid
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB00945,Acetylsalicylic acid
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB00945,Acetylsalicylic acid
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB00945,Acetylsalicylic acid
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB00945,Acetylsalicylic acid
,1841835,mean residence time in the body (MRT),"Oral aspirin is characterized by its longer mean residence time in the body (MRT), an indicator for duration of exposure, than intravenous aspirin (1.18 vs. 0.37 h).",Disposition of single-dose intravenous and oral aspirin in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,1.18,196546,DB00945,Acetylsalicylic acid
,1841835,mean residence time in the body (MRT),"Oral aspirin is characterized by its longer mean residence time in the body (MRT), an indicator for duration of exposure, than intravenous aspirin (1.18 vs. 0.37 h).",Disposition of single-dose intravenous and oral aspirin in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,0.37,196547,DB00945,Acetylsalicylic acid
,1841835,apparent elimination half-life (t1/2),The apparent elimination half-life (t1/2) of acetylsalicylic acid was also longer after oral than after intravenous administration of aspirin (40 vs. 17 min).,Disposition of single-dose intravenous and oral aspirin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),min,40,196548,DB00945,Acetylsalicylic acid
,1841835,apparent elimination half-life (t1/2),The apparent elimination half-life (t1/2) of acetylsalicylic acid was also longer after oral than after intravenous administration of aspirin (40 vs. 17 min).,Disposition of single-dose intravenous and oral aspirin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),min,17,196549,DB00945,Acetylsalicylic acid
,1841835,mean absorption time,The mean absorption time was calculated to be as long as 0.8 h.,Disposition of single-dose intravenous and oral aspirin in children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,0.8,196550,DB00945,Acetylsalicylic acid
,6436696,Systemic bioavailability,"Systemic bioavailability ranged from 46 to 51 per cent of single oral doses of 20, 40, 325, and 1300 mg of aspirin.",Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436696/),%,46 to 51,199103,DB00945,Acetylsalicylic acid
,2022012,elimination half-life,Steady-state plasma concentrations were achieved at 1 hour and declined exponentially with an elimination half-life of 24 +/- 4 minutes.,Combined administration of aspirin and a specific thrombin inhibitor in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022012/),min,24,199765,DB00945,Acetylsalicylic acid
,7320849,relative bioavailability,"The relative bioavailability of aspirin gum was 69.5 +/- 3.4% (SE), based on cumulative 4-hr urinary excretion of total salicylate after the chewing of three gum tablets for 15 min.",Relative bioavailability of aspirin gum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7320849/),%,69.5,201048,DB00945,Acetylsalicylic acid
,18094213,prostate-to-seminal vesicles concentration ratio,The prostate-to-seminal vesicles concentration ratio was 0.20 (0.0087-0.75) for salicylate and 3.6 (0.91-9.9) for desipramine.,Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094213/),,0.20,202208,DB00945,Acetylsalicylic acid
,18094213,prostate-to-seminal vesicles concentration ratio,The prostate-to-seminal vesicles concentration ratio was 0.20 (0.0087-0.75) for salicylate and 3.6 (0.91-9.9) for desipramine.,Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094213/),,3.6,202209,DB00945,Acetylsalicylic acid
,3385642,total clearance,"Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%).",Nonlinear pharmacokinetics of aspirin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),[ml] / [kg·min],45,203026,DB00945,Acetylsalicylic acid
,3385642,half-life,"Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%).",Nonlinear pharmacokinetics of aspirin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),min,8,203027,DB00945,Acetylsalicylic acid
,3385642,systemic availability,"The systemic availability of aspirin infused into the portal circulation was about 80% over a wide range of infusion rates, showing that presystemic hydrolysis of the drug occurs mainly in the gut.",Nonlinear pharmacokinetics of aspirin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),%,80,203028,DB00945,Acetylsalicylic acid
,3632148,Bioavailability,Bioavailability of aspirin from activated charcoal described by area under the curve was 19% of control.,Reversible adsorption (desorption) of aspirin from activated charcoal. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3632148/),%,19,203439,DB00945,Acetylsalicylic acid
,7848332,ED50,"In dog coronary stenosis, LCB 2853 shown a very high efficacy (ED50 = 7.2 micrograms/kg), whereas acetylsalicylic acid (ASA) was only active at 3.2 mg/kg and ticlopidine was ineffective at 12.8 mg/kg.",Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848332/),[μg] / [kg],7.2,204977,DB00945,Acetylsalicylic acid
,7848332,ED50,"In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreased the weight of thrombi in a dose related manner (ED50 = 220 micrograms/kg/min).",Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848332/),[μg] / [kg·min],220,204978,DB00945,Acetylsalicylic acid
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],1446,207416,DB00945,Acetylsalicylic acid
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],2558,207417,DB00945,Acetylsalicylic acid
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,0.5,207418,DB00945,Acetylsalicylic acid
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,1.25,207419,DB00945,Acetylsalicylic acid
,8456428,half-life,The peptide was rapidly cleared with a half-life of 36 min and a total body clearance rate for the peptide of 0.43 l kg-1 h-1.,"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8456428/),min,36,208144,DB00945,Acetylsalicylic acid
,8456428,total body clearance rate,The peptide was rapidly cleared with a half-life of 36 min and a total body clearance rate for the peptide of 0.43 l kg-1 h-1.,"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8456428/),[l] / [h·kg],0.43,208145,DB00945,Acetylsalicylic acid
,3127989,distribution volume,"Due to its very large distribution volume (10 L/kg), only less than 1% of the body load is available for removal, making hemodialysis and hemoperfusion ineffective.",Enhancement of digoxin clearance by mannitol diuresis: in vivo studies and their clinical implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127989/),[l] / [kg],10,209965,DB00945,Acetylsalicylic acid
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],12.8,212063,DB00945,Acetylsalicylic acid
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],17.9,212064,DB00945,Acetylsalicylic acid
,9120826,serum binding,"[3H]MPA serum binding (between 81 and 89 %) was similar and concentration independent in the young and elderly subjects and the erythrocyte partitioning coefficient was about 1, indicating the absence of a significant accumulation of MPA in red blood cells.",Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120826/),%,81 and 89,212126,DB00945,Acetylsalicylic acid
,9120826,partitioning coefficient,"[3H]MPA serum binding (between 81 and 89 %) was similar and concentration independent in the young and elderly subjects and the erythrocyte partitioning coefficient was about 1, indicating the absence of a significant accumulation of MPA in red blood cells.",Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120826/),,1,212127,DB00945,Acetylsalicylic acid
,3516407,AUC,"In migraine patients, there was no significant difference (p greater than 0.05) between the bioavailabilities of soluble aspirin swallowed with water (AUC = 5.7 +/- 2.3 mg h/l) and glycinated aspirin swallowed without water (AUC = 4.4 +/- 1.6 mg h/l).",A new formulation of aspirin: bioavailability and analgesic efficacy in migraine attacks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3516407/),[h·mg] / [l],5.7,212251,DB00945,Acetylsalicylic acid
,3516407,AUC,"In migraine patients, there was no significant difference (p greater than 0.05) between the bioavailabilities of soluble aspirin swallowed with water (AUC = 5.7 +/- 2.3 mg h/l) and glycinated aspirin swallowed without water (AUC = 4.4 +/- 1.6 mg h/l).",A new formulation of aspirin: bioavailability and analgesic efficacy in migraine attacks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3516407/),[h·mg] / [l],4.4,212252,DB00945,Acetylsalicylic acid
,15324530,oral bioavailability,"Oxaprozin has a high oral bioavailability (95%), with peak plasma concentrations at 3 to 5 hours after dosing.",Oxaprozin: kinetic and dynamic profile in the treatment of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15324530/),%,95,215232,DB00945,Acetylsalicylic acid
,31544007,T½ s,"IM and SC RUC-4 reached dose-dependent peak levels within 5-15 min, with T½ s between 0.28 and 0.56 hrs.","Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),h,0.28 and 0.56,216325,DB00945,Acetylsalicylic acid
,31544007,IC50,2. The RUC-4 IC50 for ADP-induced platelet aggregation was unaffected by aspirin treatment (40±9 nM vs. 37±5 nM; p=0.39).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),nM,40,216326,DB00945,Acetylsalicylic acid
,31544007,IC50,2. The RUC-4 IC50 for ADP-induced platelet aggregation was unaffected by aspirin treatment (40±9 nM vs. 37±5 nM; p=0.39).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),nM,37,216327,DB00945,Acetylsalicylic acid
,31544007,IC50,3. The RUC-4 IC50 was significantly higher in PRP prepared from PPACK-anticoagulated blood compared to citrate-anticoagulated blood using either TRAP (122±17 vs. 66±25 nM; p=0.05; n=4) or ADP (102±22 vs. 54±13; p<0.001; n=5).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),nM,122,216328,DB00945,Acetylsalicylic acid
,31544007,IC50,3. The RUC-4 IC50 was significantly higher in PRP prepared from PPACK-anticoagulated blood compared to citrate-anticoagulated blood using either TRAP (122±17 vs. 66±25 nM; p=0.05; n=4) or ADP (102±22 vs. 54±13; p<0.001; n=5).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),nM,66,216329,DB00945,Acetylsalicylic acid
,31544007,IC50,3. The RUC-4 IC50 was significantly higher in PRP prepared from PPACK-anticoagulated blood compared to citrate-anticoagulated blood using either TRAP (122±17 vs. 66±25 nM; p=0.05; n=4) or ADP (102±22 vs. 54±13; p<0.001; n=5).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),,102,216330,DB00945,Acetylsalicylic acid
,31544007,IC50,3. The RUC-4 IC50 was significantly higher in PRP prepared from PPACK-anticoagulated blood compared to citrate-anticoagulated blood using either TRAP (122±17 vs. 66±25 nM; p=0.05; n=4) or ADP (102±22 vs. 54±13; p<0.001; n=5).,"Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544007/),,54,216331,DB00945,Acetylsalicylic acid
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,10.4,219117,DB00945,Acetylsalicylic acid
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,4.5,219118,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.1,220505,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],3.3,220506,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],1.4,220507,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.5,220508,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],1.1,220509,DB00945,Acetylsalicylic acid
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.2,220510,DB00945,Acetylsalicylic acid
,3204049,oral clearance,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[l] / [h·kg],0.15,220511,DB00945,Acetylsalicylic acid
,3204049,oral clearance,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[l] / [h·kg],0.08,220512,DB00945,Acetylsalicylic acid
below,31420787,Cmin TxB2,"Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99% inhibition of serum TxB2 ( ≥ 95% inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters.","Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31420787/),[ng] / [ml],3.1,222840,DB00945,Acetylsalicylic acid
,3888490,absorption half-life,Aspirin absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes.,Clinical pharmacokinetics of the salicylates. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,5 to 16,227085,DB00945,Acetylsalicylic acid
,3888490,serum half-life,The serum half-life of aspirin is approximately 20 minutes.,Clinical pharmacokinetics of the salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,20,227086,DB00945,Acetylsalicylic acid
,8164261,IC50,"2-Guanidino-4,5-bis(4-methoxyphenyl)thiazole (3), designed from two parent compounds (itazigrel and timegadine), showed inhibitory activity of malondialdehyde (MDA, IC50 = 31 microM) production which is formed from the cyclooxygenase (CO)-catalyzed oxygenation of arachidonic acid in the synthesis of prostanoids in platelets, with vasodilatory activity (ED50 = 2.0 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,31,227473,DB00945,Acetylsalicylic acid
,8164261,ED50,"2-Guanidino-4,5-bis(4-methoxyphenyl)thiazole (3), designed from two parent compounds (itazigrel and timegadine), showed inhibitory activity of malondialdehyde (MDA, IC50 = 31 microM) production which is formed from the cyclooxygenase (CO)-catalyzed oxygenation of arachidonic acid in the synthesis of prostanoids in platelets, with vasodilatory activity (ED50 = 2.0 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,2.0,227474,DB00945,Acetylsalicylic acid
,8164261,IC50,"Further structure-activity relationship studies on 3 culminated in the preparation of 4,5-bis(4-methoxyphenyl)-2-[(1-methylpiperazin-4-yl)carbonyl]thiaz ole (10a, FR122047) which exhibited potent inhibitory activity on MDA synthesis in vitro (IC50 = 0.088 microM) and platelet aggregation in guinea pigs ex vivo (100% inhibition even 6 h after 1.0 mg/kg administration) with vasodilatory activity in vitro (ED50 = 6.2 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,0.088,227475,DB00945,Acetylsalicylic acid
,8164261,ED50,"Further structure-activity relationship studies on 3 culminated in the preparation of 4,5-bis(4-methoxyphenyl)-2-[(1-methylpiperazin-4-yl)carbonyl]thiaz ole (10a, FR122047) which exhibited potent inhibitory activity on MDA synthesis in vitro (IC50 = 0.088 microM) and platelet aggregation in guinea pigs ex vivo (100% inhibition even 6 h after 1.0 mg/kg administration) with vasodilatory activity in vitro (ED50 = 6.2 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,6.2,227476,DB00945,Acetylsalicylic acid
,8164261,IC50,"Moreover, 10a demonstrated no ulcerogenesis effect in rats even at 100 mg/kg dosage (safety margin in rats is more than 70 while that of aspirin is only 1.2) in spite of its potent CO inhibition (IC50 = 0.43 microM14), while the use of aspirin, a CO inhibitor and the most popular thromboembolic drug, is restricted by the side effect.","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM14,0.43,227477,DB00945,Acetylsalicylic acid
,8195676,half-life,"The dose of 14C-labeled alpha alpha Hb (2.4 gm Hb/kg) produced an initial plasma Hb level of 4.6 gm/dl, with a half-life in the plasma of 5.0 hours.",Diaspirin cross-linked hemoglobin: tissue distribution and long-term excretion after exchange transfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8195676/),h,5.0,227834,DB00945,Acetylsalicylic acid
,14620867,elimination rate constant,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),1/[h],1.32,228959,DB00945,Acetylsalicylic acid
,14620867,elimination half-life,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),h,0.53,228960,DB00945,Acetylsalicylic acid
,14620867,area under the plasma concentration-versus-time curve (AUC),"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],2555,228961,DB00945,Acetylsalicylic acid
,14620867,plasma clearance,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[ml] / [h·kg],472,228962,DB00945,Acetylsalicylic acid
,14620867,volume of distribution at steady state,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[l] / [kg],0.22,228963,DB00945,Acetylsalicylic acid
,14620867,AUC,"After rectal administration, the AUC for ASA was 439.4 +/- 94.55 microg x min/mL and the bioavailability was 0.17 +/- 0.037.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],439.4,228964,DB00945,Acetylsalicylic acid
,14620867,bioavailability,"After rectal administration, the AUC for ASA was 439.4 +/- 94.55 microg x min/mL and the bioavailability was 0.17 +/- 0.037.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),,0.17,228965,DB00945,Acetylsalicylic acid
,14620867,AUC,"After IG administration, the AUC for ASA was 146.70 +/- 24.90 microg x min/mL and the bioavailability was 0.059 +/- 0.013.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],146.70,228966,DB00945,Acetylsalicylic acid
,14620867,bioavailability,"After IG administration, the AUC for ASA was 146.70 +/- 24.90 microg x min/mL and the bioavailability was 0.059 +/- 0.013.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),,0.059,228967,DB00945,Acetylsalicylic acid
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.70,229330,DB00945,Acetylsalicylic acid
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.55,229331,DB00945,Acetylsalicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,30,229859,DB00945,Acetylsalicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,45,229860,DB00945,Acetylsalicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,95,229861,DB00945,Acetylsalicylic acid
,8735416,elimination rate constant (k(el)),For control animals the elimination rate constant (k(el)) and total body clearance (Cl) were 1.35 +/- 0.43 h-1 and 20.2 +/- 6.1 ml/h.kg respectively (mean +/- SD).,The pharmacokinetics of salicylate in dairy cattle are not altered by simultaneous intravenous ceftiofur sodium and DL-lysine-acetyl salicylate (aspirin). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735416/),1/[h],1.35,230311,DB00945,Acetylsalicylic acid
,8735416,total body clearance (Cl),For control animals the elimination rate constant (k(el)) and total body clearance (Cl) were 1.35 +/- 0.43 h-1 and 20.2 +/- 6.1 ml/h.kg respectively (mean +/- SD).,The pharmacokinetics of salicylate in dairy cattle are not altered by simultaneous intravenous ceftiofur sodium and DL-lysine-acetyl salicylate (aspirin). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735416/),[ml] / [h·kg],20.2,230312,DB00945,Acetylsalicylic acid
,26681756,plasma half-life,"The plasma half-life was 1.3 to 1.8 hours, and PZ-128 was nondetectable in urine.",Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681756/),h,1.3 to 1.8,232877,DB00945,Acetylsalicylic acid
,6361986,Maximum concentrations,"Maximum concentrations ranged from 0.79 to 4.25 micrograms/ml, and were found between 0.5 and 2 hours.",Treatment of juvenile rheumatoid arthritis with diclofenac sodium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361986/),[μg] / [ml],0.79 to 4.25,236071,DB00945,Acetylsalicylic acid
,6361986,Renal elimination,Renal elimination of total diclofenac ranged from 5.4 to 10.2% of the oral dose in 6 of the 7 patients.,Treatment of juvenile rheumatoid arthritis with diclofenac sodium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361986/),%,5.4 to 10.2,236072,DB00945,Acetylsalicylic acid
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],90.9,239639,DB00945,Acetylsalicylic acid
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],64.7,239640,DB00945,Acetylsalicylic acid
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[ml] / [min],87.3,239641,DB00945,Acetylsalicylic acid
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),,120.6,239642,DB00945,Acetylsalicylic acid
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],622,241008,DB00945,Acetylsalicylic acid
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],3428,241009,DB00945,Acetylsalicylic acid
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],8416,241010,DB00945,Acetylsalicylic acid
,24944359,area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞),"Pentoxifylline exhibited nonlinear kinetic characteristics, with median area under the plasma concentration-time curve from time 0 to infinity(AUC0-∞) values of 622, 3428, 8416, and 10,347 ng/mL · h for dose levels 1 to 4, respectively, on study day 1.",Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944359/),[ng] / [h·ml],"10,347",241011,DB00945,Acetylsalicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,178.9,241179,DB00945,Acetylsalicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,136.8,241180,DB00945,Acetylsalicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,137.0,241181,DB00945,Acetylsalicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,93.0,241182,DB00945,Acetylsalicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,167.0,241183,DB00945,Acetylsalicylic acid
,2719746,half-life,After intravenous administration fosfosal plasma levels decreased rapidly showing a half-life of 2.7 min in rats and 6.7 min in dogs.,Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),min,2.7,241856,DB00945,Acetylsalicylic acid
,2719746,half-life,After intravenous administration fosfosal plasma levels decreased rapidly showing a half-life of 2.7 min in rats and 6.7 min in dogs.,Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),min,6.7,241857,DB00945,Acetylsalicylic acid
,2719746,half-life,"The half-life of salicylic acid was 13.8 and 7.1 h for rats and dogs, respectively.",Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),h,13.8,241858,DB00945,Acetylsalicylic acid
,2719746,half-life,"The half-life of salicylic acid was 13.8 and 7.1 h for rats and dogs, respectively.",Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),h,7.1,241859,DB00945,Acetylsalicylic acid
,1184427,half-time of absorption,"Despite slow absorption (half-time of absorption, 2.91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective.",Pharmacokinetics and dosage of aspirin in cattle. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184427/),h,2.91,243264,DB00945,Acetylsalicylic acid
,1184427,biologic half-life,"Despite slow absorption (half-time of absorption, 2.91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective.",Pharmacokinetics and dosage of aspirin in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184427/),min,32,243265,DB00945,Acetylsalicylic acid
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,20,245762,DB00945,Acetylsalicylic acid
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,6,245763,DB00945,Acetylsalicylic acid
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,2 to 3,245764,DB00945,Acetylsalicylic acid
,13957,half-life,The half-life of methadone averages 25 hours.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,25,245765,DB00945,Acetylsalicylic acid
,13957,half-life,Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,4,245766,DB00945,Acetylsalicylic acid
,13957,half-life,The half-life of naloxone in serum following distribution is 64 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,64,245767,DB00945,Acetylsalicylic acid
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,68,246405,DB00945,Acetylsalicylic acid
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,60,246406,DB00945,Acetylsalicylic acid
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,59,246407,DB00945,Acetylsalicylic acid
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,63,246408,DB00945,Acetylsalicylic acid
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247723,DB00945,Acetylsalicylic acid
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247724,DB00945,Acetylsalicylic acid
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247725,DB00945,Acetylsalicylic acid
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247726,DB00945,Acetylsalicylic acid
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],0.67,247727,DB00945,Acetylsalicylic acid
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],3.76,247728,DB00945,Acetylsalicylic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00945,Acetylsalicylic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00945,Acetylsalicylic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00945,Acetylsalicylic acid
,2013838,terminal elimination half-life,The terminal elimination half-life following intravenous dosing (10 mg/kg) was 3.36 +/- 0.85 min (n = 15) with the clearance being 8.40 +/- 1.24 L/(kg.hr).,The pharmacokinetics of aspirin in rats and the effect of buffer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),min,3.36,249883,DB00945,Acetylsalicylic acid
,2013838,clearance,The terminal elimination half-life following intravenous dosing (10 mg/kg) was 3.36 +/- 0.85 min (n = 15) with the clearance being 8.40 +/- 1.24 L/(kg.hr).,The pharmacokinetics of aspirin in rats and the effect of buffer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),[l] / [hr·kg],8.40,249884,DB00945,Acetylsalicylic acid
,2013838,absolute bioavailable dose,The absolute bioavailable dose of aspirin was 56.6 +/- 10.4% (n = 6) following its administration in an unbuffered solution while it was only 31.8 +/- 8.0% (n = 6) following administration in the buffered solution.,The pharmacokinetics of aspirin in rats and the effect of buffer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),%,56.6,249885,DB00945,Acetylsalicylic acid
,2013838,absolute bioavailable dose,The absolute bioavailable dose of aspirin was 56.6 +/- 10.4% (n = 6) following its administration in an unbuffered solution while it was only 31.8 +/- 8.0% (n = 6) following administration in the buffered solution.,The pharmacokinetics of aspirin in rats and the effect of buffer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),%,31.8,249886,DB00945,Acetylsalicylic acid
,2013838,absolute bioavailable doses,The corresponding values of the absolute bioavailable doses were 43.4 +/- 3.7% and 25.5 +/- 1.8% following intraintestinal administration.,The pharmacokinetics of aspirin in rats and the effect of buffer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),%,43.4,249887,DB00945,Acetylsalicylic acid
,2013838,absolute bioavailable doses,The corresponding values of the absolute bioavailable doses were 43.4 +/- 3.7% and 25.5 +/- 1.8% following intraintestinal administration.,The pharmacokinetics of aspirin in rats and the effect of buffer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013838/),%,25.5,249888,DB00945,Acetylsalicylic acid
,22515556,maximum (peak) plasma concentration (C(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],733,250416,DB00945,Acetylsalicylic acid
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.0,250417,DB00945,Acetylsalicylic acid
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],210,250418,DB00945,Acetylsalicylic acid
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.1,250419,DB00945,Acetylsalicylic acid
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],4130,250420,DB00945,Acetylsalicylic acid
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],1325,250421,DB00945,Acetylsalicylic acid
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],305,250422,DB00945,Acetylsalicylic acid
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],121,250423,DB00945,Acetylsalicylic acid
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],724,250424,DB00945,Acetylsalicylic acid
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],764,250425,DB00945,Acetylsalicylic acid
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3983,250426,DB00945,Acetylsalicylic acid
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3986,250427,DB00945,Acetylsalicylic acid
,27978468,flow rate,The separation of two components was achieved by using an ACQUITY UPLC ®BEH C18 Column (1.7μm 2.1×100mm) by gradient elution using water (containing 0.2% formic acid) and acetonitrile (containing 0.2% formic acid) as the mobile phase at a flow rate of 0.2mL/min.,Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27978468/),[ml] / [min],0.2,250704,DB00945,Acetylsalicylic acid
,3665485,area under the plasma norethindrone versus time curve,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),[ng] / [h·ml],0.72,252326,DB00945,Acetylsalicylic acid
,3665485,area under the plasma norethindrone versus time curve,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),[ng] / [h·ml],0.49,252327,DB00945,Acetylsalicylic acid
,3665485,oral bioavailability,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),%,56,252328,DB00945,Acetylsalicylic acid
,3665485,oral bioavailability,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),%,38,252329,DB00945,Acetylsalicylic acid
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00945,Acetylsalicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,6.19,252576,DB00945,Acetylsalicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,12.2,252577,DB00945,Acetylsalicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,4.47,252578,DB00945,Acetylsalicylic acid
,18030066,area under the concentration-time curve (AUC0-tlast),Active metabolite area under the concentration-time curve (AUC0-tlast) after prasugrel 60-mg (594 ng.hr/mL) was 2.2 times that after clopidogrel 600-mg.,Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030066/),[h·ng] / [ml],594,252650,DB00945,Acetylsalicylic acid
,12040334,apparent clearance,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),[l] / [h],0.733,252945,DB00945,Acetylsalicylic acid
,12040334,distribution volume,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),l,5.24,252946,DB00945,Acetylsalicylic acid
,12040334,plasma half-life,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),h,5,252947,DB00945,Acetylsalicylic acid
,7837833,half-lives of absorption (t1/2 (dis)),"When using 0.9% NaCl, the half-lives of absorption (t1/2 (dis)) of pentacaine and stobadine were (mean +/- SD) 23.2 +/- 7.8 min and 20.8 +/- 7.2 min, respectively.",On the absorption of drugs using chronic dog ileal loop method. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837833/),min,23.2,253145,DB00945,Acetylsalicylic acid
,7837833,half-lives of absorption (t1/2 (dis)),"When using 0.9% NaCl, the half-lives of absorption (t1/2 (dis)) of pentacaine and stobadine were (mean +/- SD) 23.2 +/- 7.8 min and 20.8 +/- 7.2 min, respectively.",On the absorption of drugs using chronic dog ileal loop method. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7837833/),min,20.8,253146,DB00945,Acetylsalicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.71,255499,DB00945,Acetylsalicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],15.8,255500,DB00945,Acetylsalicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],2.42,255501,DB00945,Acetylsalicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.89,255502,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.86,255503,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],60.5,255504,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.68,255505,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.96,255506,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],59.1,255507,DB00945,Acetylsalicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.77,255508,DB00945,Acetylsalicylic acid
,24105106,Tmax,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,0.55-0.92,256028,DB00945,Acetylsalicylic acid
,24105106,t1/2 kel,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,0.35-0.65,256029,DB00945,Acetylsalicylic acid
,24105106,Tmax,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,2.35-3.03,256030,DB00945,Acetylsalicylic acid
,24105106,t1/2 kel,"After single-dose administration, triflusal was rapidly absorbed with a mean Tmax of 0.55-0.92 h and a mean t1/2 kel of 0.35-0.65 h, HTB was absorbed with a mean Tmax of 2.35-3.03 h and a mean t1/2 kel of 52.5-65.57 h.","Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24105106/),h,52.5-65.57,256031,DB00945,Acetylsalicylic acid
,20598402,half-life,"The pharmacokinetic study indicated that SKI-I-Asp cleaved efficiently to form SKI-I and the half-life of SKI-I was increased from approximately 7 h in SKI-I to approximately 10 h in SKI-I-Asp injected mice, thereby prolonging its effect.",Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20598402/),h,7,256474,DB00945,Acetylsalicylic acid
,20598402,half-life,"The pharmacokinetic study indicated that SKI-I-Asp cleaved efficiently to form SKI-I and the half-life of SKI-I was increased from approximately 7 h in SKI-I to approximately 10 h in SKI-I-Asp injected mice, thereby prolonging its effect.",Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20598402/),h,10,256475,DB00945,Acetylsalicylic acid
,21814444,T(max),"In the present study, Products A and B showed their T(max), C(max), AUC(0-24), AUC(0- ∞,) MRT, and K(a) values as 2.5 h, 2589 ± 54.79 ng/ml, 9623 ± 112.87 ng.h/ml, 9586 ± 126.22 ng.h/ml, 3.6 ± 0.10 h, and 0.3698 ± 0.003 h (-1) for Product A and 3.0 h, 2054 ± 55.79 ng/ml, 9637 ± 132.87 ng.h/ml, 9870 ± 129.22 ng.h/ml, 4.76 ± 0.10 h, and 0.3812 ± 0.002 h (-1) for Product B, respectively.",Comparative bioavailability studies of citric acid and malonic acid based aspirin effervescent tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814444/),h,2.5,257242,DB00945,Acetylsalicylic acid
,21814444,"AUC(0- ∞,) MRT","In the present study, Products A and B showed their T(max), C(max), AUC(0-24), AUC(0- ∞,) MRT, and K(a) values as 2.5 h, 2589 ± 54.79 ng/ml, 9623 ± 112.87 ng.h/ml, 9586 ± 126.22 ng.h/ml, 3.6 ± 0.10 h, and 0.3698 ± 0.003 h (-1) for Product A and 3.0 h, 2054 ± 55.79 ng/ml, 9637 ± 132.87 ng.h/ml, 9870 ± 129.22 ng.h/ml, 4.76 ± 0.10 h, and 0.3812 ± 0.002 h (-1) for Product B, respectively.",Comparative bioavailability studies of citric acid and malonic acid based aspirin effervescent tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814444/),[ng] / [ml],2589,257243,DB00945,Acetylsalicylic acid
,21814444,K(a),"In the present study, Products A and B showed their T(max), C(max), AUC(0-24), AUC(0- ∞,) MRT, and K(a) values as 2.5 h, 2589 ± 54.79 ng/ml, 9623 ± 112.87 ng.h/ml, 9586 ± 126.22 ng.h/ml, 3.6 ± 0.10 h, and 0.3698 ± 0.003 h (-1) for Product A and 3.0 h, 2054 ± 55.79 ng/ml, 9637 ± 132.87 ng.h/ml, 9870 ± 129.22 ng.h/ml, 4.76 ± 0.10 h, and 0.3812 ± 0.002 h (-1) for Product B, respectively.",Comparative bioavailability studies of citric acid and malonic acid based aspirin effervescent tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814444/),-1·h,0.3698,257244,DB00945,Acetylsalicylic acid
,21814444,K(a),"In the present study, Products A and B showed their T(max), C(max), AUC(0-24), AUC(0- ∞,) MRT, and K(a) values as 2.5 h, 2589 ± 54.79 ng/ml, 9623 ± 112.87 ng.h/ml, 9586 ± 126.22 ng.h/ml, 3.6 ± 0.10 h, and 0.3698 ± 0.003 h (-1) for Product A and 3.0 h, 2054 ± 55.79 ng/ml, 9637 ± 132.87 ng.h/ml, 9870 ± 129.22 ng.h/ml, 4.76 ± 0.10 h, and 0.3812 ± 0.002 h (-1) for Product B, respectively.",Comparative bioavailability studies of citric acid and malonic acid based aspirin effervescent tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814444/),[ng] / [ml],2054,257245,DB00945,Acetylsalicylic acid
,1905593,half-life,The clearance of Bat-PA from rabbits exhibited biexponential elimination kinetics; approximately 80% was cleared by the relatively slow beta phase (half-life of 17.1 minutes).,Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905593/),min,17.1,259145,DB00945,Acetylsalicylic acid
,29329092,flow rate,The separation of six components was achieved by using an ACQUITY UPLC ®BEH C18 column (1.7μm 2.1×100mm) by gradient elution using water (containing 0.2% formic acid) and acetonitrile (containing 0.2% formic acid) as the mobile phase at a flow rate of 0.2mL/min.,Effect of aspirin on the pharmacokinetics and absorption of panax notoginseng saponins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29329092/),[ml] / [min],0.2,264612,DB00945,Acetylsalicylic acid
,23526241,AUC0-t,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],52.69,265364,DB00945,Acetylsalicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 378.62,265365,DB00945,Acetylsalicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[1] / [h],0.75,265366,DB00945,Acetylsalicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.17,265367,DB00945,Acetylsalicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.50,265368,DB00945,Acetylsalicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[ng] / [ml],985.90,265369,DB00945,Acetylsalicylic acid
,12643328,plasma concentration,"Ten minutes after the PEG-Hirudin injection/starting the infusion, mean plasma concentration was 3.1 microgram/mL and aPTT, ECT, and ACT were prolonged up to 80, 309, and 233 seconds, respectively.",Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643328/),,3.1,265454,DB00945,Acetylsalicylic acid
,12643328,plasma concentration,During the last 8 hours of the 24-hour infusion mean PEG-Hirudin plasma concentration was 1.3 microgram/mL.,Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643328/),[μg] / [ml],1.3,265455,DB00945,Acetylsalicylic acid
,12643328,BT,"At 6 hours after administration, on day 3 mean BT was 6.5 minutes after PEG-Hirudin alone, 18.2 minutes after ASA alone, and 32.9 minutes after combined administration of ASA and PEG-Hirudin.",Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643328/),min,6.5,265456,DB00945,Acetylsalicylic acid
,12643328,BT,"At 6 hours after administration, on day 3 mean BT was 6.5 minutes after PEG-Hirudin alone, 18.2 minutes after ASA alone, and 32.9 minutes after combined administration of ASA and PEG-Hirudin.",Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643328/),min,18.2,265457,DB00945,Acetylsalicylic acid
,12643328,BT,"At 6 hours after administration, on day 3 mean BT was 6.5 minutes after PEG-Hirudin alone, 18.2 minutes after ASA alone, and 32.9 minutes after combined administration of ASA and PEG-Hirudin.",Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643328/),min,32.9,265458,DB00945,Acetylsalicylic acid
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,94,265467,DB00945,Acetylsalicylic acid
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,93,265468,DB00945,Acetylsalicylic acid
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,79,265469,DB00945,Acetylsalicylic acid
,18397691,Maximal inhibition,"Maximal inhibition after a single dose and at steady state were as follows: 94% and 93% (COX-1), and 79% and 85% (COX-2).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),%,85,265470,DB00945,Acetylsalicylic acid
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],35.48,265471,DB00945,Acetylsalicylic acid
,18397691,IC50,"For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).",Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397691/),[μM] / [l],64.62,265472,DB00945,Acetylsalicylic acid
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00945,Acetylsalicylic acid
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,96.0,268604,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,94.9,268605,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,98.7,268606,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268607,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268608,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268609,DB00945,Acetylsalicylic acid
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268610,DB00945,Acetylsalicylic acid
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268611,DB00945,Acetylsalicylic acid
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268612,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,36.2,268613,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,20.7,268614,DB00945,Acetylsalicylic acid
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,40.7,268615,DB00945,Acetylsalicylic acid
<,11307804,plasma half-life,90% patients had a plasma half-life for AR-C69931XX of <9 min.,"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9,268616,DB00945,Acetylsalicylic acid
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,124,269313,DB00945,Acetylsalicylic acid
,10963905,mechanical thresholds,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),g,63,269314,DB00945,Acetylsalicylic acid
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,19,269315,DB00945,Acetylsalicylic acid
,10963905,thermal latencies,A concentration of 1.0% carrageenan (intraplantar) reduced mechanical thresholds from 124+/-5 to 63+/-3 g and thermal latencies from 19+/-0.4 to 4.7+/-0.9 s as determined 4 h after injection.,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),s,4.7,269316,DB00945,Acetylsalicylic acid
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],17,269317,DB00945,Acetylsalicylic acid
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],>,269318,DB00945,Acetylsalicylic acid
,10963905,D(30),"The D(30) values for RPR100893 and SR140333 were estimated to be 17 and >100 mg kg(-1), respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],100,269319,DB00945,Acetylsalicylic acid
,10963905,D(30),The D(30) value for SDZ NKT 343 was 3.89 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],3.89,269320,DB00945,Acetylsalicylic acid
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],1.85,269321,DB00945,Acetylsalicylic acid
,10963905,ED(50),"For comparison, morphine inhibited the carrageenan-induced mechanical and thermal hyperalgesia with an ED(50) of 1.85 and 2.51 mg kg(-1) s.c., respectively.",Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),[mg] / [kg],2.51,269322,DB00945,Acetylsalicylic acid
,10963905,maximum reversal,RPR100893 was significantly less effective with a maximum reversal of 30% at 100 mg kg(-1).,Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963905/),%,30,269323,DB00945,Acetylsalicylic acid
,30465727,Cmax,Oral reserpine administration demonstrated low plasma concentrations with a Cmax of 0.2 ± 0.06 ng/mL and a prolonged half-life of 23.6 ± 6.24 h.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),[ng] / [ml],0.2,269652,DB00945,Acetylsalicylic acid
,30465727,half-life,Oral reserpine administration demonstrated low plasma concentrations with a Cmax of 0.2 ± 0.06 ng/mL and a prolonged half-life of 23.6 ± 6.24 h.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),h,23.6,269653,DB00945,Acetylsalicylic acid
,30465727,Cmax at steady state,Simulations over a dose range of 2-8 μg/kg predicted Cmax at steady state between 0.06-0.9 ng/mL.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),[ng] / [ml],0.06-0.9,269654,DB00945,Acetylsalicylic acid
,8100628,recovery,Mean +/- SD recovery of salicylate were WBI 48.6 +/- 5.4% and ipecac-charcoal 37.0 +/- 2.6% from urine (p < 0.01).,Low-volume whole bowel irrigation and salicylate absorption: a comparison with ipecac-charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100628/),%,48.6,270237,DB00945,Acetylsalicylic acid
,8100628,recovery,Mean +/- SD recovery of salicylate were WBI 48.6 +/- 5.4% and ipecac-charcoal 37.0 +/- 2.6% from urine (p < 0.01).,Low-volume whole bowel irrigation and salicylate absorption: a comparison with ipecac-charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100628/),%,37.0,270238,DB00945,Acetylsalicylic acid
,20006565,absolute recovery,The mean absolute recovery for all tested molecules was always found to be close to 100%.,HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006565/),%,100,270692,DB00945,Acetylsalicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],7.54,270861,DB00945,Acetylsalicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],22.65,270862,DB00945,Acetylsalicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],43.2,270863,DB00945,Acetylsalicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],70,270864,DB00945,Acetylsalicylic acid
,12906745,oral bioavailability,"Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t(max) varying widely between 2 and 9 h.","Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),%,93,272101,DB00945,Acetylsalicylic acid
,12906745,t(max),"Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t(max) varying widely between 2 and 9 h.","Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),h,2 and 9,272102,DB00945,Acetylsalicylic acid
,12906745,terminal half-life,Rofecoxib is eliminated predominantly by hepatic metabolism with a terminal half-life of approximately 17 h during steady state.,"Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),h,17,272103,DB00945,Acetylsalicylic acid
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,118,273139,DB00945,Acetylsalicylic acid
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,310,273140,DB00945,Acetylsalicylic acid
